GDIT and NightDragon Announce Partnership to Accelerate Emerging Technology Adoption for U.S. Government

Companies will deliver advanced solutions for national security, civilian and health missions.

FALLS CHURCH, Va., May 13, 2026 (GLOBE NEWSWIRE) — General Dynamics Information Technology (GDIT), a business unit of General Dynamics, and NightDragon, a SecureTech investment and advisory firm, announced today a new strategic collaboration agreement aimed to accelerate the U.S. government’s adoption of emerging security technologies.

Through this collaboration, GDIT will work with NightDragon to align leading cybersecurity, national security, and defense companies in NightDragon’s portfolio with U.S. government programs supported by GDIT. This will enable accelerated insertion of innovative commercial technology in complex, highly regulated government environments in areas such as artificial intelligence, cybersecurity and autonomyacross all six domains, including air, sea, land, space, and cyber. The agreement will facilitate co- investment in technical solutions for national security, civilian and health missions.

“Our collaboration with NightDragon reinforces our commitment to bringing the latest commercial technology to address federal agencies’ toughest mission challenges,” said Amy Gilliland, GDIT’s president. “We look forward to leveraging our collective strengths to further accelerate innovation and rapidly deliver mission-ready technology solutions that are proven, secure and scalable.”

“By combining NightDragon’s investment in emerging technologies with GDIT’s scale and mission expertise, we can accelerate the journey from innovation to impact, ensuring breakthrough technologies are ready to address the most complex and evolving national security challenges,” said Dave DeWalt, founder and chief executive officer, NightDragon. “In today’s dynamic and increasingly contested security landscape, especially as cyber and defense converge, scaling visionary companies to deliver advanced capabilities has never been more critical for maintaining strategic advantage and protecting our national interests.”

The collaboration builds on the existing partnerships that GDIT, and other General Dynamics business units, have with cyber and defense companies in NightDragon’s portfolio. For example, GDIT has already won more than $120 million in contracts by partnering with NightDragon portfolio companies, including Horizon3.ai, to secure critical infrastructure from cyber threats at military bases.

“As a NightDragon portfolio company, we’ve already seen firsthand how the combination of NightDragon’s strategic support and GDIT’s deep mission expertise can accelerate growth and open meaningful opportunities. With active collaborations and deals in the pipeline, this partnership is helping companies like Horizon3.ai bring innovative cybersecurity capabilities to support critical national security missions faster and at greater scale,” said Snehal Antani, co-founder and chief executive officer, Horizon3.ai.

This strategic collaboration agreement expands GDIT’s existing emerging technology program. Last year, GDIT partnered with dozens of new emerging technology companies, and is rapidly developing new proofs of concept for integration into critical missions. Through these partnerships, GDIT is co-building solutions, testing them in research and development labs nationwide and applying them in operational mission environments. The agreement with NightDragon is also a key part of the company’s broader Vision, Innovation and Acceleration (VIA) strategy, which emphasizes deepening partnerships with commercial technology companies.

GDIT is a business unit of General Dynamics (NYSE:GD), a global aerospace and defense company that offers a broad portfolio of products and services in business aviation; ship construction and repair; land combat vehicles, weapons systems and munitions; and technology products and services. General Dynamics employs more than 110,000 people worldwide and generated $52.6 billion in revenue in 2025.

More information about General Dynamics Information Technology is available at www.gdit.com. More information about General Dynamics is available at www.gd.com.

NightDragon is an investment and advisory firm focused on growth and late-stage investments within the SecureTech industry, including cybersecurity, defense, safety, and national security technologies. Its platform and vast industry network provide unparalleled threat insights, deal flow, market leverage and operating expertise to drive portfolio company growth and increase shareholder value. Founded by Dave DeWalt, the NightDragon team has more than 25 years of operational and market expertise leading technology companies such as Documentum, EMC, Siebel Systems (Oracle), McAfee, Mandiant, Avast and FireEye. Read more about NightDragon at www.nightdragon.com.



Sarah Kuranda Vallone
NightDragon
9788440862
[email protected]

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

PR Newswire

– Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer –


Continued to Execute Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis, with Top-Line Data Expected by End of 2026 –

– Raised $200 Million in an Oversubscribed Private Placement, with Potential for up to an Additional $200 Million –

NEW YORK, May 13, 2026 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update.

“We are fast approaching a highly pivotal juncture, with the anticipated top-line data readout of the twin phase 3 ENSURE trials of our lead asset, orally available nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in relapsing multiple sclerosis (RMS), expected by the end of 2026,” stated Daniel Vitt, Ph.D., Chief Executive Officer of Immunic. “In anticipation, we strengthened our leadership team with the recent appointment of Dr. Michael A. Panzara as Chief Medical Officer. Mike brings deep expertise in neurology and a proven track record of advancing multiple sclerosis (MS) therapies through late-stage clinical development and global regulatory approvals. Additionally, we enhanced our Board of Directors with the appointment of Jon Congleton, who has nearly four decades of biopharmaceutical leadership experience. Earlier in the quarter, Simona Skerjanec, M.Pharm, M.B.A., who joined Immunic’s Board of Directors in July 2024, has been elevated to interim Chairperson of the Board and Thor Nagel, Principal at BVF Partners L.P., has been appointed as a member of the Board. Together, these key appointments are intended to best position the company for successful execution of our late-stage development priorities and prepare for potential commercialization.”

Dr. Vitt continued, “As important, in February, we closed an oversubscribed private placement financing of up to $400 million in gross proceeds, with $200 million received upfront. This highly successful transaction signals investors’ continued confidence in Immunic and has provided the resources we need to advance our programs through key milestones and to continue our transition into a commercial-stage company. The initial proceeds are expected to fund our operations through the completion of our phase 3 ENSURE trials in RMS and our planned RMS New Drug Application (NDA) submission in the United States in mid-2027. The funds will also support continued investment in our development organization and launch readiness. At the same time, we remain focused on expanding the opportunity for vidofludimus calcium beyond RMS, which is supported by the growing body of data from our phase 2 CALLIPER trial in progressive MS (PMS) and our plan to initiate a confirmatory phase 3 program in primary progressive MS (PPMS) later this year.”

Jason Tardio, President and Chief Operating Officer of Immunic, added, “We believe vidofludimus calcium has the potential to offer a transformative approach to disease modification in MS. Unlike currently available oral therapies that primarily target inflammatory pathways, vidofludimus calcium is designed to deliver both direct neuroprotective effects through Nurr1 activation and anti-inflammatory activity via selective DHODH inhibition. In clinical trials to date, vidofludimus calcium has demonstrated a favorable safety and tolerability profile. Taken together, these attributes may support a compelling benefit-risk profile in the global MS market, which is projected to exceed $30 billion by the early 2030s.”

First Quarter 2026 and Subsequent Highlights

  • April 2026: Appointed accomplished biopharmaceutical executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer, to lead the company’s development organization, including clinical development, medical affairs, and regulatory affairs. Dr. Panzara succeeds Andreas Muehler, M.D., M.B.A., who will continue to support the company as a consultant.
  • April 2026: Effected 1-for-10 reverse stock split of the outstanding shares of common stock as of April 27, 2026.
  • April 2026: Regained compliance with Nasdaq minimum bid price requirement (Rule 5550(a)(2)) for continued listing, following receipt of a written notice on March 27, 2026.
  • March 2026: Appointed Jon Congleton, a seasoned biopharmaceutical executive with nearly 40 years of experience spanning drug development, commercialization and corporate leadership, to the Board of Directors.
  • March 2026: Announced grant of a key European patent from the European Patent Office (EPO) directed to label-relevant dosing regimens of vidofludimus calcium. The patent is expected to provide protection into 2038 and may be eligible for a Supplementary Protection Certificate (SPC), which could extend market exclusivity potentially into 2043. This patent was previously granted by the United States Patent and Trademark Office (USPTO) in 2023.
  • February 2026: Completed an oversubscribed private placement financing of up to $400 million in gross proceeds, led by existing investor BVF Partners L.P. with participation from Aberdeen Investments, Avidity Partners, Coastlands Capital, EcoR1 Capital, Janus Henderson Investors, OrbiMed, RA Capital Management, TCGX, Trails Edge Capital Partners, Vivo Capital, Woodline Partners LP, and other institutional investors. A total of $200 million in gross proceeds to Immunic was received upon closing on February 17, 2026.
    • Elevated Simona Skerjanec, former SVP, Global Head of Neuroscience and Rare Diseases at Roche, to Interim Chairperson of the Board of Directors. Dr. Duane Nash, former Chairman, remains a member of the Board. Appointed Thor Nagel, Principal at BVF Partners L.P., to the Board. Plans underway for further Board refreshment to support the company’s evolution into a commercial-stage organization.
    • Initiated search for a new Chief Executive Officer with deep commercial expertise in neurology to lead Immunic into its next stage of growth and commercialization. Subsequently, Dr. Vitt will return to his roots and transition to a new senior executive role focused on scientific strategy and portfolio advancement, while remaining on the Board.
  • February 2026: Presented additional data from the phase 2 CALLIPER trial of vidofludimus calcium in patients with PMS at the ACTRIMS Forum 2026 in San Diego, California. The findings, presented in two poster presentations, provide additional evidence of vidofludimus calcium’s effects on key biological drivers of disease progression, including antiviral immune responses linked to Epstein-Barr virus (EBV) and magnetic resonance imaging (MRI) markers of both acute-focal and chronic-compartmentalized inflammation. The findings further reinforce Immunic’s belief that vidofludimus calcium has the potential to address underlying mechanisms of disease progression in MS patients.

Anticipated Clinical Milestones

  • Vidofludimus calcium in MS:

    • Top-line data from the twin phase 3 ENSURE-1 and ENSURE-2 trials in RMS is expected by the end of 2026. Subsequently, Immunic plans to submit an NDA in the United States in mid-2027, with a targeted potential regulatory approval date in 2028.
    • Initiation of a phase 3 clinical program in PPMS is expected later this year and is estimated to take approximately 3.5 to 4 years to complete.
  • IMU-856: The company is currently exploring strategic alternatives for the IMU-856 program and is open to discussing potential financing, licensing or partnering options with interested parties.

Financial and Operating Results

  • Research and Development (R&D) Expenses were $25.6 million for the three months ended March 31, 2026, as compared to $21.5 million for the three months ended March 31, 2025. The $4.1 million increase reflects (i) a $2.9 million increase in external development costs related to the vidofludimus calcium program, (ii) a $1.0 million increase in personnel expenses, $0.7 million of which was related to non-cash stock compensation and (iii) a $0.2 million increase related to costs across numerous categories.
  • General and Administrative (G&A) Expenses were $7.6 million for the three months ended March 31, 2026, as compared to $5.3 million for the same period ended March 31, 2025. The $2.3 million increase was due to (i) a $2.0 million increase related to personnel expenses, of which $1.8 million was related to non-cash stock compensation, (ii) a $0.2 million increase in legal and consultancy expenses, (iii) a $0.2 million increase in marketing expenses, which was partially offset by a $0.1 million decrease related to costs across numerous categories.
  • Interest Income was $0.8 million for the three months ended March 31, 2026, as compared to $0.2 million for the three months ended March 31, 2025. The $0.6 million increase was due to a higher average cash balance as a result of the February 2026 Private Placement.
  • Other Income (Expense) was ($0.1) million for the three months ended March 31, 2026, as compared to $1.2 million for the same period ended March 31, 2025. The $1.3 million decrease was primarily attributable to (i) a $1.1 million grant income of the German Federal Ministry of Finance recognized in the first quarter 2025 and no grant income in 2026 and (ii) a $0.2 million decrease across numerous categories.
  • Net Loss for the three months ended March 31, 2026, was approximately $32.6 million, or $1.08 per basic and diluted share, based on 30,136,324 weighted average common shares outstanding, compared to a net loss of approximately $25.5 million, or $2.51 per basic and diluted share, based on 10,134,443 weighted average common shares outstanding for the same period ended March 31, 2025.
  • Cash and Cash Equivalents as of March 31, 2026 were $186.6 million. With these funds, Immunic expects to be able to fund its operations into late 2027.

About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company’s lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). The company’s development pipeline also includes earlier-stage programs, including IMU-856 and IMU-381, aimed at building a broader therapeutics platform addressing neurodegenerative, chronic inflammatory, and autoimmune-related diseases. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic’s development programs and the targeted diseases; the potential for Immunic’s development programs to safely and effectively target diseases; preclinical and clinical data for Immunic’s development programs; the feasibility of advancing vidofludimus calcium to a confirmatory phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials, anticipated clinical milestones and regulatory approvals; the nature, strategy and focus of the company and further updates with respect thereto; the development and commercial potential of any product candidates of the company; expectations regarding the capitalization, resources and ownership structure of the company; and the executive and board structure of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, and the ability to raise sufficient capital to continue as a going concern, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.

Contact Information


Immunic, Inc.

Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
[email protected]

US IR Contact

Rx Communications Group
Paula Schwartz
+1 917 633 7790
[email protected]

US Media Contact

KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
[email protected]

Financials


Immunic, Inc.


Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

(Unaudited)


Three Months

 Ended March 31,


2026


2025

Operating expenses:

Research and development

$    25,626

$    21,533

General and administrative

7,609

5,292

Total operating expenses

33,235

26,825

Loss from operations

(33,235)

(26,825)

Other income:

Interest income

760

183

Other  income (expense), net

(113)

1,169

Total other income

647

1,352

Net loss

$   (32,588)

$   (25,473)

Net loss per share, basic and diluted

$     (1.08)

$     (2.51)

Weighted-average common shares outstanding, basic and diluted

30,136,324

10,134,443


Immunic, Inc.


Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

(Unaudited)



March 31,
2026




December 31,
2025




(Unaudited)



Assets

Current assets:

Cash and cash equivalents

$     186,629

$          15,483

Prepaid expenses and other current assets

2,130

7,386

Total current assets

188,759

22,869

Property and equipment, net

566

608

Right-of-use assets, net

417

575

Total assets

$     189,742

$          24,052



Liabilities and Stockholders’ Equity (Deficit)

Current liabilities:

Accounts payable

$       11,011

$          10,138

Accrued expenses

22,432

18,645

Other current liabilities

4,920

1,835

Total current liabilities

38,363

30,618

Long-term liabilities

Operating lease liabilities

146

107

Total long-term liabilities

146

107

Total liabilities

38,509

30,725

Commitments and contingencies

Stockholders’ equity (deficit):

Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued
or outstanding as of March 31, 2026 and December 31, 2025

Common stock, $0.0001 par value; 500,000,000 shares authorized as of March
31, 2026 and December 31, 2025 and 13,621,483 and 12,038,263 shares issued
and outstanding as of March 31, 2026 and December 31, 2025, respectively.

11

9

Additional paid-in capital

789,324

599,241

Accumulated other comprehensive income

3,057

2,648

Accumulated deficit

(641,159)

(608,571)

Total stockholders’ equity (deficit)

151,233

(6,673)

Total liabilities and stockholders’ equity (deficit)

$     189,742

$          24,052

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-inc-reports-first-quarter-2026-financial-results-and-provides-corporate-update-302769899.html

SOURCE Immunic, Inc.

Valens Semiconductor Reports First Quarter 2026 Results

PR Newswire

Key Financial Highlights:

  • Q1 2026 revenues: $16.9 million, exceeding the top end of our guidance
  • Q1 2026 gross margin: 62.2% GAAP; 65.2% non-GAAP, exceeding the top end of our guidance
  • Cash, cash equivalents and short-term deposits as of March 31, 2026: $86.1 million

HOD HASHARON, Israel, May 13, 2026 /PRNewswire/ — Valens Semiconductor Ltd. (NYSE: VLN), a leader in high-performance connectivity, today reported financial results for the first quarter ended March 31, 2026.

“The first quarter of 2026 exceeded our expectations, as we once again beat the top end of our guidance,” said Yoram Salinger, CEO of Valens Semiconductor. “In Audio-Video, we’re continuing to see increased adoption of our VS6320 and VS3000 chipsets, as additional products based on these chips hit the market. In Automotive, Valens is focused on pushing the MIPI A-PHY ecosystem forward. In Q1, we publicly demonstrated the first three-company interoperable SerDes link, reinforcing one of the core value propositions of any industry standard by introducing a multi-vendor ecosystem for OEMs.”

 

 


Q1 2026 Financial Highlights:

  • Q1 2026 revenues reached $16.9 million, exceeding our guidance of $16.3-$16.7 million, compared to $19.4 million in Q4 2025 and $16.8 million in Q1 2025.
    • Q1 2026 Cross-Industry Business (“CIB”) revenues accounted for approximately 65% of total revenues at $11.0 million compared to $13.9 million in Q4 2025 and $11.7 million in Q1 2025.
    • Q1 2026 Automotive revenues accounted for approximately 35% of total revenues at $5.9 million, compared to $5.5 million in Q4 2025 and $5.1 million in Q1 2025.
  • Q1 2026 GAAP gross margin was 62.2% (non-GAAP gross margin was 65.2%), above the guidance of 57%-59%. This is compared to a GAAP gross margin of 60.5% for Q4 2025 and 62.9% for Q1 2025 (non-GAAP gross margin of 63.9% in Q4 2025 and 66.7% in Q1 2025). On a segment basis, Q1 2026 gross margin from the CIB was 70.8% and gross margin from Automotive was 46.2%. This compares to Q4 2025 gross margins on a segment basis of 66.4% and 45.9%, respectively, and Q1 2025 gross margins on a segment basis of 69.1% and 48.4%, respectively. The increase in gross margin of the CIB compared to Q4 2025 was primarily due to product mix.
  • Q1 2026 GAAP net loss amounted to $(8.3) million, compared to a net loss of $(8.8) million in Q4 2025 and a net loss of $(8.3) million in Q1 2025.
  • Q1 2026 adjusted EBITDA was a loss of $(5.5) million, which was lower than the previous guidance range of a $(7.9)-$(7.5) million adjusted EBITDA loss. This compares to an adjusted EBITDA loss of $(4.3) million in Q4 2025 and an adjusted EBITDA loss of $(4.3) million in Q1 2025.
  • Cash, cash equivalents and short-term deposits as of March 31, 2026, were $86.1 million and no debt. This compares to a cash balance of $92.6 million as of December 31, 2025 and $112.5 million as of March 31, 2025.


Financial Outlook for Q2 2026

For Q2 2026, Valens expects revenues to range between $17.2 million to $17.6 million, gross margin to range between 60% to 62%, and adjusted EBITDA loss to range between $(4.9) million to $(4.4) million.

Disclaimer: Valens Semiconductor does not provide GAAP net profit (loss) guidance as certain elements of net profit (loss), including share-based compensation expenses and warrant valuations, are not predictable due to the high variability and difficulty of making accurate forecasts. Adjusted EBITDA is a non-GAAP measure. See the tables below for additional information regarding this and other non-GAAP metrics used in this release.


Conference Call Information

Valens Semiconductor will host a conference call today, Wednesday, May 13, 2026, at 8:30 a.m. Eastern Time (ET) to discuss its first quarter 2026 financial results and business outlook. To access this call, dial (at least 10 minutes before the scheduled time)- USA & Canada (Toll-Free): (888) 672-2415; United States (New York): (646) 307-1952; United Kingdom (Toll-Free): +44 800 524 4763; United Kingdom (London): +44 20 8610 3532; Israel (Tel Aviv): +972 3 375 1755; Conference ID: 9028589.
A live webcast of the conference call will be available via the investor relations section of Valens Semiconductor’s website at Valens – Financials – Quarterly Results. The live webcast can also be accessed by clicking HERE. A replay of the conference call will be available on Valens Semiconductor’s website shortly after the call concludes.


NYSE Rule 203.01 Annual Financial Report Announcement

Pursuant to Rule 203.01 of the New York Stock Exchange Manual, Valens Semiconductor Ltd. hereby announces to holders of its ordinary shares that its Annual Report on Form 20-F for 2025 (including its full year 2025 audited financial statements), filed with the U.S. Securities and Exchange Commission on February 25, 2026, is available in the investor relations section of its website at https://investors.valens.com/financials/secfilings/default.aspx. While the company encourages the sustainable approach of downloading and reading the report online, hard copies of the 2025 Annual Report will be provided free of charge, upon request, as follows: Valens Semiconductor Ltd., 8 Hanagar St. POB 7152, Hod Hasharon 4501309, Israel, or by emailing: [email protected].


Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding our anticipated future results, including financial results, our anticipated growth projections, our ability to concentrate our resources on our core businesses, our expectations regarding future revenues, gross margin, and adjusted EBITDA loss, and future economic and market conditions. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Valens Semiconductor’s (“Valens”) management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Valens Semiconductor. These forward-looking statements are subject to a number of risks and uncertainties, including the cyclicality of the semiconductor industry; the effect of inflation and a rising interest rate environment on our customers and industry; the ability of our customers to absorb inventory; competition in the semiconductor industry, and the failure to introduce new technologies and products in a timely manner to compete successfully against competitors; if Valens fails to adjust its supply chain volume due to changing market conditions or fails to estimate its customers’ demand; disruptions in relationships with any one of Valens’ key customers or suppliers; any difficulty selling Valens’ products if customers do not design its products into their product offerings; Valens’ dependence on winning selection processes; even if Valens succeeds in winning selection processes for its products, Valens may not generate timely or sufficient net sales or margins from those wins; sustained yield problems or other delays or quality events in the manufacturing process of products; our ability to effectively manage, invest in, grow, and retain our sales force, research and development capabilities, marketing team and other key personnel; our ability to timely adjust product prices to customers following price increase by the supply chain; our ability to adjust our inventory level due to reduction in demand due to inventory buffers accrued by customers; our expectations regarding the outcome of any future litigation in which we are named as a party; our ability to adequately protect and defend our intellectual property and other proprietary rights; risks related to our use of AI technologies; our ability to successfully integrate or otherwise achieve anticipated benefits from acquired businesses; the market price and trading volume of the Valens ordinary shares may be volatile and could decline significantly; further deterioration of macroeconomic conditions due to ongoing global political and economic uncertainty, including with respect to China-Taiwan relations and increasing trade and other tariff-related tensions (as our current guidance assumes the estimated production and/or demand impact on us of current tariff conditions); political, economic, governmental and tax consequences, as well as geopolitical tensions, associated with our incorporation and location in Israel; and those factors discussed in Valens’ Form 20-F filed with the SEC on February 25, 2026 under the heading “Risk Factors,” and other documents of Valens filed, or to be filed, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Valens does not presently know or that Valens currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Valens’ expectations, plans or forecasts of future events and views as of the date of this press release. Valens anticipates that subsequent events and developments may cause Valens’ assessments to change. However, while Valens may elect to update these forward-looking statements at some point in the future, Valens specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Valens’ assessment as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.


About Valens Semiconductor

Valens Semiconductor is a leader in high-performance connectivity, enabling customers to transform the digital experiences of people worldwide. Valens’ chipsets are integrated into countless devices from leading customers, powering state-of-the-art audio-video installations, next-generation videoconferencing, and enabling the evolution of ADAS and autonomous driving. Pushing the boundaries of connectivity, Valens sets the standard everywhere it operates, and its technology forms the basis for the leading industry standards such as HDBaseT® and MIPI A-PHY. For more information, visit https://www.valens.com/.

 


VALENS SEMICONDUCTOR LTD.


SUMMARY OF FINANCIAL RESULTS


(U.S. Dollars in thousands, except per share amounts)


Three Months Ended


March 31,


2026


2025

Revenues

16,859

16,828

Gross Profit

10,487

10,582

Gross Margin

62.2 %

62.9 %

Net Loss

(8,290)

(8,308)

Working Capital1

91,279

119,820

Cash, Cash Equivalents and Short-Term Deposits2

86,117

112,540

Net Cash Used in Operating Activities

(5,132)

(7,611)



Non-GAAP Financial Data

Non-GAAP Gross Margin3

65.2 %

66.7 %

Adjusted EBITDA Loss4

(5,466)

(4,346)

 Non-GAAP Loss Per Share5 (in U.S. Dollars)

$(0.05)

$(0.03)

 


VALENS SEMICONDUCTOR LTD.


CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS


(U.S. Dollars in thousands, except share and per share amounts)


Three Months Ended


March 31,


2026


2025


REVENUES

16,859

16,828


COST OF REVENUES

(6,372)

(6,246)


GROSS PROFIT

10,487

10,582


OPERATING EXPENSES:

Research and development expenses

(10,294)

(10,590)

Sales and marketing expenses 

(5,396)

(5,607)

General and administrative expenses

(4,017)

(3,667)

Change in earnout liability

282

(174)


TOTAL OPERATING EXPENSES

(19,425)

(20,038)


OPERATING LOSS

(8,938)

(9,456)

Financial income, net

673

1,238


LOSS BEFORE INCOME TAXES

(8,265)

(8,218)


INCOME TAXES

(27)

(93)


LOSS AFTER INCOME TAXES

(8,292)

(8,311)

Equity in earnings of investee

2

3


NET LOSS


(8,290)


(8,308)


EARNINGS PER SHARE DATA:



BASIC AND DILUTED NET LOSS PER
ORDINARY SHARE

6
 (in U.S. Dollars)


$(0.08)


$(0.08)


WEIGHTED AVERAGE NUMBER OF SHARES
AND VESTED RSUS USED


IN COMPUTING NET LOSS PER ORDINARY
SHARE


105,047,377


105,255,959

Change in unrealized losses on cash flow
hedges

(364)

(542)


TOTAL COMPREHENSIVE LOSS


(8,654)


(8,850)

 


VALENS SEMICONDUCTOR LTD.


CONDENSED CONSOLIDATED BALANCE SHEETS


(U.S. Dollars in thousands)


ASSETS


March 31, 2026


December 31, 2025


CURRENT ASSETS 

Cash and cash equivalents

28,970

27,863

 Short-term deposits

57,147

64,733

 Restricted Short-term deposit

1,144

1,132

 Trade accounts receivable

10,475

9,971

 Inventories

10,906

10,117

 Prepaid expenses and other current assets

4,316

4,842


TOTAL CURRENT ASSETS


112,958


118,658


LONG-TERM ASSETS:

 Property and equipment, net

2,776

2,901

 Operating lease right-of-use assets

6,645

6,901

 Intangible assets

3,526

3,762

 Goodwill

1,847

1,847

 Other assets

668

632


TOTAL LONG-TERM ASSETS


15,462


16,043


TOTAL ASSETS


128,420


134,701


LIABILITIES AND EQUITY



CURRENT LIABILITIES


21,679


22,934


LONG-TERM LIABILITIES

Non-current operating leases liabilities

6,390

6,717

Other long-term liabilities

111

67


TOTAL LONG-TERM LIABILITIES


6,501


6,784


TOTAL LIABILITIES


28,180


29,718


TOTAL SHAREHOLDERS’ EQUITY


100,240


104,983


TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY 


128,420


134,701

 


VALENS SEMICONDUCTOR LTD.


CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS


(U.S. Dollars in thousands)


Three Months Ended


March 31,


2026


2025


CASH FLOW FROM OPERATING ACTIVITIES


  Net loss for the period

(8,290)

(8,308)


  Adjustments to reconcile net loss to net cash used in operating activities:

 Income and expense items not involving cash flows:

Depreciation and amortization

618

770

Stock-based compensation 

3,136

4,166

Exchange rate differences

149

140

Realized and unrealized Loss (gain) on non-designated derivative instruments

5

(204)

Interest on short-term deposits

(327)

517

                 Change in earnout liability

(282)

174

Reduction in the carrying amount of ROU assets

310

418

Equity in earnings of investee, net of dividend received

(2)

(3)


 Changes in operating assets and liabilities: 

Trade accounts receivable 

(509)

(1,800)

Prepaid expenses and other current assets

235

825

Inventories

(789)

(762)

Other assets 

(24)

(115)

Current Liabilities

973

(3,196)

Change in operating lease liabilities

(379)

(230)

Other long-term liabilities

44

(3)


  Net cash used in operating activities 


(5,132)


(7,611)


CASH FLOWS FROM INVESTING ACTIVITIES:

  Investment in short-term deposits

(5,664)

(30,005)

  Maturities of short-term deposits 

13,565

53,278

  Purchase of property and equipment

(437)

(357)

Derivative instruments of non-designated hedges

(5)

(265)


  Net cash provided by investing activities


7,459


22,651


CASH FLOWS FROM FINANCING ACTIVITIES:

Repurchase of Ordinary Shares

(9,585)

Earnout Payment

(1,962)

Exercise of stock options

775

188


  Net
cash
 provided by (used in) financing activities


(1,187)


(9,397)


  Effect of exchange rate changes on cash and cash equivalents

(33)

(69)


INCREASE IN CASH AND CASH EQUIVALENTS

1,107

5,574


CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD

27,863

35,423


CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD


28,970


40,997


SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES

Trade accounts payable on account of property and equipment

180

62

Operating lease liabilities arising from obtaining operating right-of-use assets

54

213


VALENS SEMICONDUCTOR LTD.


RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES


(U.S. Dollars in thousands)

The following table provides a reconciliation of Net loss to Adjusted EBITDA, a non-GAAP measure. Adjusted EBITDA is defined as Net profit (loss) before financial income (expense), net, income taxes, equity in earnings of investee and depreciation and amortization, further adjusted to exclude share-based compensation and change in earnout liability, which may vary from period-to-period. We caution investors that amounts presented in accordance with our definition of Adjusted EBITDA may not be comparable to similar measures disclosed by other issuers, because not all issuers calculate Adjusted EBITDA in the same manner. Adjusted EBITDA should not be considered as an alternative to Net loss or any other performance measures derived in accordance with GAAP or as an alternative to cash flows from operating activities as a measure of our liquidity.

 

Although we provide guidance for Adjusted EBITDA, we are not able to provide guidance for projected Net profit (loss), the most directly comparable GAAP measures. Certain elements of Net profit (loss), including share-based compensation expenses and warrant valuations, are not predictable due to the high variability and difficulty of making accurate forecasts. As a result, it is impractical for us to provide guidance on Net profit (loss) or to reconcile our Adjusted EBITDA guidance without unreasonable efforts. Consequently, no disclosure of projected Net profit (loss) is included. For the same reasons, we are unable to address the probable significance of the unavailable information.


Three Months Ended


March 31,


2026


2025


Net Loss


(8,290)


(8,308)


Adjusted to exclude the following:

Change in earnout liability

(282)

174

Financial income, net

(673)

(1,238)

Income taxes

27

93

Equity in earnings of investee

(2)

(3)

Depreciation and amortization

618

770

Stock-based compensation expenses

3,136

4,166


Adjusted EBITDA Loss


(5,466)


(4,346)

 


VALENS SEMICONDUCTOR LTD.


RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES


(U.S. Dollars in thousands, except per share amounts)

The following tables provide a calculation of the GAAP Loss per share and reconciliation to Non-GAAP Loss per share.


Three Months Ended


March 31,



GAAP Loss per Share


2026


2025


GAAP Net Loss used for computing Loss per Share


(8,290)


(8,308)



Earnings Per Share Data:


GAAP Loss per Share (in U.S. Dollars)


$(0.08)


$(0.08)


Weighted average number of shares and vested RSUs used in computing net loss per ordinary share


105,047,377


105,255,959


Three Months Ended


March 31,



Non-GAAP Loss per Share7


2026


2025

GAAP Net Loss

(8,290)

(8,308)

Adjusted to exclude the following:

Stock based compensation

3,136

4,166

Depreciation and amortization

618

770

Change in earnout liability

(282)

174


Total Non-GAAP Loss used for computing Loss per Share


(4,818)


(3,198)



Earnings Per Share Data:


Non-GAAP Loss per Share (in U.S. Dollars)


$(0.05)


$(0.03)


Weighted average number of shares and vested RSUs used in computing net loss per ordinary share



105,047,377


105,255,959

 

 

 

1 Working Capital is calculated as Total Current Assets, less Total Current Liabilities, as of the last day of the period.

2 As of the last day of the period.

3 Non-GAAP Gross Margin is defined as: GAAP Gross Profit excluding share-based compensation and depreciation and amortization expenses, divided by revenue. For the three months ended March 31, 2026, and 2025, share-based compensation and depreciation and amortization expenses were $508 thousand and $650 thousand, respectively.

4 Adjusted EBITDA is defined as Net profit (loss) before financial income (expense), net, income taxes, equity in earnings of investee, and depreciation and amortization, further adjusted to exclude share-based compensation and change in fair value of Forfeiture Shares and in earnout liability, which may vary from period-to-period. We caution investors that amounts presented in accordance with our definition of Adjusted EBITDA may not be comparable to similar measures disclosed by other issuers, because not all issuers calculate Adjusted EBITDA in the same manner. Adjusted EBITDA should not be considered as an alternative to Net loss or any other performance measures derived in accordance with GAAP or as an alternative to cash flows from operating activities as a measure of our liquidity. Please refer to the appendix at the end of this press release for a reconciliation to the most directly comparable measure in accordance with GAAP.

5 See reconciliation of GAAP to non-GAAP financial measures.

6 See footnote 5

7 The company calculates its non-GAAP Loss per Share as GAAP Net Loss adjusted to exclude the following: Stock based compensation, depreciation and amortization, and the change in fair value of earnout liability divided by the weighted average number of shares used in calculation of net loss per share.

Infographic: https://mma.prnewswire.com/media/2979022/Valens_Semiconductor_Infographic.jpg
Logo: https://mma.prnewswire.com/media/2309625/4474760/Valens_Semiconductor_Logo.jpg

 

 


For more information, please contact:

Investor Contacts:

Michal Ben Ari
Investor Relations Manager
Valens Semiconductor Ltd.
[email protected]

Miri Segal
MS-IR IR for Valens
[email protected]

Media Contact:

Yoni Dayan
Head of Communications
Valens Semiconductor Ltd.
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/valens-semiconductor-reports-first-quarter-2026-results-302770764.html

SOURCE Valens Semiconductor

Eos Energy Enterprises and Cerberus Capital Management Announce Frontier Power USA to Deploy American-Made Long Duration Energy Storage at Scale

Frontier Power USA is expected to be a purpose-built independent development and investment company utilizing Eos’ vertically integrated technology stack to accelerate gigawatt-scale deployment of American-made energy storage


  • 2 GWh Firm Capacity Reservation Agreement: 

    Eos entered into a 2 GWh Capacity Reservation Agreement securing dedicated manufacturing capacity for Frontier Power USA

  • ~$1.5 Billion Lender-Grade Technology Performance Insurance

    : A 15-year non-cancellable technology performance insurance policy framework secured with Ariel Green to accelerate multi-year project bankability

  • Cerberus $100 Million Commitment: 

    Cerberus is anchoring Frontier Power USA with a $100 million equity commitment to accelerate project deployments and is extending its existing Eos lockup through year-end 2026

  • Eos Investment

    : Eos is expected to fund its equity contribution through a pro rata rights offering targeting approximately $150 million, allowing existing shareholders to maintain proportional economic interest in Eos’ participation​​​​​​​​​​ in Frontier USA

EDISON, N.J. and NEW YORK, May 13, 2026 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE), America’s leading innovator in designing, manufacturing, and providing zinc-based long duration energy storage (LDES) systems sourced and manufactured in the United States, and Cerberus Capital Management, L.P. (“Cerberus”), one of the country’s largest alternative investment firms, today announced the intention to capitalize Frontier Power USA, an independent development and investment company established to build, own, and operate a diversified portfolio of long-duration battery energy storage projects deploying Eos’ proprietary zinc bromide based Z3 technology with the strategy of becoming an Independent Power Producer (IPP).

Frontier Power USA is expected to unify three core capabilities that have historically sat across multiple stakeholders: Eos’ vertically integrated technology stack, Cerberus’s institutional capital and operating experience, and a performance wrap to be provided by Ariel Green, which underwrites Z3 performance. The performance wrap underpins the structure and will allow project debt to achieve investment-grade characteristics at competitive terms. This combination is designed to compress the project lifecycle from commitment to first energy cycle and convert Eos’ opportunity pipeline or projects with secured interconnection and offtake into funded, under construction assets.

Manufacturers in capital-intensive industries, from aviation to power generation, have long used financing vehicles to accelerate customer deployment, and those platforms have generated significant value for stakeholders over time. Frontier USA is targeting to be the first application of that proven playbook to long-duration energy storage.

Accelerated Project Deployment

Eos and Frontier Power USA entered into a firm 2 GWh capacity reservation agreement, expanding Eos’ March 31, 2026 backlog. Frontier Power USA is expected to deploy this capacity across commercial and industrial applications, AI data centers, and utility-scale projects, drawing from a multi GWh project pipeline which is under active development.

Firm Technology Performance Insurance (TPI) with Ariel Green 
Simplifying project bankability and accelerating asset deployment, Frontier Power USA has secured a firm Technology Performance Insurance (TPI) framework with Ariel Green, a division of Ariel Re and a leader in clean energy insurance. The framework contemplates a 15-year non-cancellable coverage, which will be sized at the project level with a multi-year total policy capacity of up to approximately $1.5 billion, written through highly rated insurance markets including syndicates at a Lloyd’s of London consortium (A+/AA-).

This framework is designed to meet the risk and underwriting standards of institutional lenders. By providing consistent, long-term performance protection, the structure enables projects to be financed on investment-grade terms, supporting longer tenors and a lower cost of capital. Alongside this policy, Frontier Power USA is evaluating two complementary debt financing paths under the TPI framework: investment-grade-rated debt placed with institutional investors and captive insurance platforms, and project-level facilities with traditional commercial bank lenders.

Anchored by Institutional Capital & Extensive Operating Experience

Cerberus Capital Management is anchoring Frontier Power USA with a $100 million equity commitment and is concurrently extending its existing Eos lock-up through year end 2026; Cerberus is expected to receive Eos warrants, as well as controlling equity in Frontier Power USA in exchange for its commitment. The funding of Cerberus’s equity commitment is subject to certain closing conditions. As a standalone entity, Frontier Power USA will separate project-level capital from the Eos corporate balance sheet, allowing Eos to focus on technology development, manufacturing, and project execution. Frontier Power USA is expected to be led by a CEO with a deep operating track record in energy storage development and project finance, supported by a dedicated origination and structuring team.

Rights Offering 
To fund its equity contribution in Frontier Power USA, Eos intends to launch a rights offering targeting approximately $150 million. In the rights offering, existing Eos common shareholders, including retail investors, would receive a distribution of subscription rights to purchase Eos securities along with receiving expected warrants. These rights would be distributed based on how much Eos common stock an existing shareholder owns as of the record date for the distribution, providing the opportunity to maintain proportional economic interest in Eos’ participation in Frontier. The structure is designed to broaden access, preserve flexibility for non-participating holders through transferability, and limit incremental dilution for those who exercise. The terms of any distribution of rights have not yet been determined, and the distribution is subject to conditions including board declaration of a distribution, shareholder approval of the increase in our authorized shares and certain other consents under our existing debt agreements.

Strategic Rationale
Frontier Power USA is expected to be a first-of-its kind: A vertically integrated BESS developer and planned IPP with direct OEM access from cell to software. The company will have direct access to an OEM at the cell IP level, through module and system architecture to the proprietary software layer, creating end-to-end integration that reduces the risks in third party assembled supply chains. It’s a purpose-built independent developer and IPP working in direct partnership with Eos and an expected embedded fully-funded financing vehicle.

It is expected to be a self-reinforcing growth engine. Cash flow generated by operating projects will be systematically reinvested into the platform, funding new project origination, accelerating Eos equipment deployment, and compounding the value of the integrated technology stack.

Together, the platform is intended to:

  • Establish a scalable capital platform for gigawatt-scale Eos Z3 deployment in markets where long-duration storage is uniquely positioned to address grid resiliency and load growth
  • Optimize project economics through dedicated financing, expanded institutional capital access, and direct relationships with offtakes and infrastructure partners
  • Enable Eos shareholders to participate alongside strategic and institutional partners in long-term project-level value creation

Management Commentary

“We believe that Frontier Power USA will bring the speed and ability to scale that the grid urgently needs, at a time when the opportunity set is being driven by energy security requirements and sustained growth in power demand from electrification and AI. By pairing the company’s execution and deployment platform with Eos’ differentiated long-duration storage technology and expanding U.S. manufacturing base, we believe this model creates a credible path to delivering storage capacity at scale. The platform is designed to translate proven technology into reliable, deployable assets that can keep pace with the system’s evolving needs.”



Aaron Maczonis, Managing Director at Cerberus Capital Management

.

“As energy storage projects scale, bridging the gap between technology innovation and associated liabilities becomes essential. This transaction through Frontier Power USA shows how TPI can play that role, supporting both bankability and repeatable platform growth across the U.S.”



Jamie Daggett, Energy Storage Practice Lead, Ariel Green

“Frontier Power USA changes the speed of long-duration storage financing and deployment, allowing customers to have faster access to capital and deep expertise in project development. We feel confident that this will give Eos a new growth trajectory as we continue to expand manufacturing capacity. The platform pairs our integrated technology stack with institutional capital and a lender-ready performance framework that is designed to deliver what matters most: electrons to the grid.”

Mastrangelo concluded, “We believe the planned structure maintains shareholder alignment by allowing Eos investors to participate pro rata in Frontier’s Power USA’s growth via Eos ownership while ensuring project capital is governed independently and on arm’s-length commercial terms.”



Joe Mastrangelo, Chief Executive Officer Eos Energy

About Eos Energy Enterprises
Eos is accelerating the shift to American energy independence with positively ingenious solutions that transform how the world stores power. The Company’s BESS features the innovative Znyth™ technology, a proven chemistry with readily available non-precious earth components, that is the pre-eminent safe, non-flammable, secure, stable, and scalable alternative to conventional technology. The Company’s BESS is ideal for utility-scale, microgrid, commercial, and industrial long-duration energy storage applications (i.e., 4 to 16+ hours), and provides customers with significant operational flexibility to effectively address current and future increased grid demand and complexity. For more information about Eos (NASDAQ: EOSE), visit www.eose.com

About Cerberus
Founded in 1992, Cerberus is a global alternative investment firm with approximately $70 billion in assets across complementary credit, real estate, and private equity strategies. The firm invests across the capital structure where it believes its integrated investment platforms and proprietary operating capabilities can help improve performance and drive long-term value. Cerberus’ tenured teams have experience working collaboratively across asset classes, sectors, and geographies as they seek to achieve strong risk-adjusted returns for investors. For more information, visit www.cerberus.com

About Ariel Green

Ariel Green provides Technology Performance Insurance (TPI) for the clean energy industry, deploying capital through customized long-term and non-cancellable risk management solutions. As a division of Ariel Re, a premier (re)insurance business and underwriters at Lloyd’s, our team is supported by the world’s leading insurance and reinsurance marketplace. Ariel Green brings deep expertise and a collaborative approach to developing insurance products that enable clean energy projects to secure financing, get built and begin operations. Learn more at www.arielgreen.com.

Contacts

Eos Investor Relations: [email protected]
Eos Media: [email protected]
Cerberus Media: [email protected]

Forward-Looking Statements and Important Information

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding our expected revenue, for the fiscal year ended December 31, 2026, our path to profitability and strategic outlook, statements regarding orders backlog and opportunity pipeline, statements regarding the joint venture, the transactions related thereto, and any anticipated benefits of the joint venture, statements regarding our expectation that we can continue to increase product volume on our state-of-the-art manufacturing line, statements regarding our future expansion and its impact on our ability to scale up operations and increase margins, statements regarding the expected impact of DawnOSTM on efficiency operating costs, and grid-coordination, statements regarding the launch of IndensityTM and our expectations for the architecture and its expected energy density, statements regarding our expectation that we can continue to strengthen our overall supply chain, statements that refer to outlook, projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are based on our management’s beliefs, as well as assumptions made by, and information currently available to, them. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected.

Factors which may cause actual results to differ materially from current expectations include, but are not limited to: changes adversely affecting the business in which we are engaged; our ability to forecast trends accurately; our ability to generate cash, service indebtedness and incur additional indebtedness; our ability to raise financing in the future; our ability to obtain stockholder approval of an increase to our authorized common stock; our ability to complete a rights offering to raise funds for purposes of capitalizing Frontier Power USA; risks associated with the joint venture, including the risk that the joint venture will not be completed on the anticipated terms if at all; risks associated with the credit agreement with Cerberus, including risks of default, and dilution of outstanding common stock; our customers’ ability to secure project financing; the amount of final tax credits available to our customers or to Eos pursuant to the Inflation Reduction Act, including potential impacts from any repeal or modifications of the legislation; the timing and availability of future funding under the Department of Energy Loan Facility; our ability to continue to develop efficient manufacturing processes to scale and to forecast related costs and efficiencies accurately; fluctuations in our revenue and operating results; competition from existing or new competitors; our ability to convert firm order backlog and pipeline to revenue; risks associated with security breaches in our information technology systems; risks related to legal proceedings or claims; risks associated with evolving energy policies in the United States and other countries and the potential costs of regulatory compliance; risks associated with changes to the U.S. trade environment; our ability to maintain the listing of our shares of common stock on NASDAQ; our ability to grow our business and manage growth profitably, maintain relationships with customers and suppliers and retain our management and key employees; risks related to adverse changes in general economic conditions, including inflationary pressures and increased interest rates; risk from supply chain disruptions and other impacts of geopolitical conflict; changes in applicable laws or regulations; the possibility that Eos may be adversely affected by other economic, business, and/or competitive factors; other factors beyond our control; risks related to adverse changes in general economic conditions; and other risks and uncertainties indicated.

The forward-looking statements contained in this press release are also subject to additional risks, uncertainties, and factors, including those more fully described in the Company’s most recent filings with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K and subsequent reports on Forms 10-Q and 8-K. Further information on potential risks that could affect actual results will be included in the subsequent periodic and current reports and other filings that the Company makes with the Securities and Exchange Commission from time to time. Moreover, the Company operates in a very competitive and rapidly changing environment, and new risks and uncertainties may emerge that could have an impact on the forward-looking statements contained in this press release.

Forward-looking statements speak only as of the date they are made. Should one or more of these risks or uncertainties materialize or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

This press release includes information about a proposed series of transactions, including the formation of a joint venture between us and CCM Frontier JV Holdco, LLC, an affiliate of Cerberus Capital Management (“Cerberus”), an investment by Cerberus of $100 million in the joint venture, a rights offering by us to fund our investment in the joint venture, and certain commercial arrangements to be entered into between us and Frontier Power USA Parent, LLC (collectively, the “Proposed Transactions”). We and Cerberus have entered into a binding term sheet with respect to the Proposed Transactions. However, the completion of the Proposed Transactions remains subject to a number of conditions and uncertainties, including the receipt of our shareholder approval to increase the authorized shares of our common stock, completion of the proposed rights offering, the receipt of required third party-approvals, including the approval of the Department of Energy, the negotiations and entry into definitive agreements for the Proposed Transactions and the negotiation of certain terms of the Proposed Transactions. While we currently intend to take the actions within our control to complete the Proposed Transactions on the contemplated terms and timeline, there can be no assurances that the Proposed Transactions will be completed on the contemplated terms or timeline or that the Proposed Transactions will be completed at all.

This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities, including any securities in a rights offering. There shall be no offer to sell or the solicitation of an offer to buy or any sale of subscription rights, common stock, warrants or any other securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any rights offering will be made pursuant to our effective shelf registration statement, including a base prospectus, under the Securities Act of 1933, as amended, and a prospectus supplement to be filed with the SEC. Any rights offering is subject to board declaration of a distribution, shareholder approval of the increase in our authorized shares and certain other consents under our existing debt agreements.



Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress


–Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for i


nterim analysis first quarter calendar year 2027




–Company to host conference call and webcast today at 8:00 a.m. ET—

MIAMI, FL, May 13, 2026 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal 2026 second quarter ended March 31, 2026, and provided a corporate update.

“We are extremely pleased with the progress of the enrollment of the Phase 2b PLATEAU clinical trial to evaluate the effect of enobosarm 3mg on total body weight, fat mass, lean mass, physical function, bone mineral density and safety in older patients who have obesity and receiving a semaglutide GLP-1 RA treatment for weight reduction. We are on track for presenting the results of the interim analysis which is expected in Q1 calendar year 2027,” said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru Inc.

Veru Obesity Program – Study of Enobosarm in combination with GLP-1 RA for higher quality weight reduction

Phase 2b PLATEAU Clinical Study – Actively enrolling

Phase 2b PLATEAU clinical trial is a double-blind, placebo-controlled study to evaluate the effect of enobosarm 3mg on total body weight, fat mass, lean mass, physical function, bone mineral density and safety in approximately 200 older patients (age ≥ 65 years) who have obesity (BMI ≥ 35) and are initiating semaglutide treatment for weight reduction. The Phase 2b PLATEAU study is designed to assess the ability of enobosarm treatment to break through the weight loss plateau observed in patients with obesity receiving GLP-1 RA treatment by preserving muscle mass and physical function to achieve clinically meaningful incremental weight reduction by 68 weeks. The primary efficacy endpoint of the study is the percent change from baseline in total body weight at 68 weeks. An interim analysis will be conducted at 36 weeks to assess the percent change from baseline in lean body mass and fat mass, as measured by DXA scan. The key secondary endpoints are total fat mass, total lean mass, physical function (stair climb test), mobility disability assessment, bone mineral density, and patient reported outcome questionnaires for physical function, HbA1c, and insulin resistance.

Semaglutide was selected as the GLP-1 RA for the Phase 2b PLATEAU study to build on Veru’s previous clinical experience using enobosarm in combination with semaglutide in the positive Phase 2 QUALITY clinical study. Further, the clinical data from the Phase 2b PLATEAU clinical trial using injectable semaglutide may support the use of oral semaglutide in combination with oral enobosarm in future Phase 3 clinical studies. In contrast, there is no approved oral formulation for tirzepatide. The Principal Investigator for the Phase 2b PLATEAU clinical trial is Steven Heymsfield, MD, a Professor and the Director of the Body Composition-Metabolism Laboratory at the Pennington Biomedical Research Center in Baton Rouge, Louisiana. Dr. Heymsfield was also the Principal Investigator of Veru’s Phase 2 QUALITY clinical study.

An interim analysis to assess change in lean body mass and fat mass as measured by DXA will be conducted at 36 weeks with data expected in the first quarter of calendar year 2027. Final topline clinical data is expected in the fourth quarter of calendar year 2027.

Phase 2b QUALITY Clinical Study – Completed

The Phase 2b QUALITY clinical study was a positive multicenter, double-blind, placebo-controlled, randomized, dose-finding clinical trial designed to evaluate the safety and efficacy of enobosarm 3 mg, enobosarm 6 mg, or placebo as a treatment to augment fat loss and to prevent muscle loss in 168 older patients (≥60 years of age) receiving semaglutide (Wegovy®) for weight reduction. After the efficacy dose-finding portion of the Phase 2b QUALITY clinical trial was completed at 16 weeks, participants continued into a Phase 2b maintenance extension study where all patients discontinued semaglutide treatment, but continued receiving placebo, enobosarm 3 mg, or enobosarm 6 mg as monotherapy in a double-blind fashion for 12 weeks. The Phase 2b QUALITY and Maintenance Extension clinical trial was a positive study that demonstrated that preserving lean mass and physical function with enobosarm plus semaglutide led to greater fat loss during the 16 week active weight loss period. While weight loss was similar across treatment groups in this short 16 week study, we anticipate that preservation of lean mass and function will lead to increased energy expenditure, and this effect coupled with the direct effects of enobosarm on the additional selective reduction in fat mass will result in incremental weight reduction in a longer 68 week clinical study in patients who have obesity.

Second Quarter Financial Summary: Fiscal 2026 vs Fiscal 2025

  • Research and development expenses decreased to $3.1 million from $3.9 million
  • General and administrative expenses decreased to $4.1 million from $5.2 million
  • Operating loss from continuing operations decreased to $7.2 million from $8.1 million
  • Net loss decreased to $2.7 million, or $0.12 per share, compared to $7.9 million, or $0.54 per share

Year-to-Date Financial Summary: Fiscal 2026 vs Fiscal 2025

  • Research and development expenses decreased to $4.5 million from $9.6 million
  • General and administrative expenses decreased to $8.2 million from $10.4 million
  • Operating loss from continuing operations decreased to $12.6 million from $18.4 million
  • Net loss decreased to $8.1 million, or $0.37 per share, compared to $16.8 million, or $1.15 per share

Balance Sheet Information

  • ​​​​​Cash, cash equivalents and restricted cash were $27.6 million as of March 31, 2026 versus $15.8 million as of September 30, 2025

Event Details

The audio webcast will be accessible under the Home page and Investors page of the Company’s website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call. An archived version of the audio webcast will be available for replay on the Company’s website for approximately three months. A telephonic replay will be available at approximately 12:00 p.m. ET by dialing 1-855-669-9658 (domestic) or 1-412-317-0088 (international), passcode 8826955, for one week.

About Veru Inc.

Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass to improve body composition and physical function which is expected to result in clinically meaningful incremental weight reduction versus GLP-1 RA therapy alone. Sabizabulin, a microtubule disruptor, is being developed for the treatment of chronic inflammation related to atherosclerotic cardiovascular disease.

Forward-Looking Statements

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, express or implied statements related to the planned design, enrollment, timing, commencement, interim, topline and full data readout timing, scope and regulatory pathways for the continued development of enobosarm in patients with obesity, including the PLATEAU Phase 2b study; the planned design, number of sites, timing, endpoints, patient population and patient size of such trial and whether the PLATEAU trial will successfully meet any of its primary or secondary endpoints; whether the results of the Phase 2b QUALITY study and the extension maintenance study of enobosarm, including weight loss, preservation of lean mass and physical function and loss of fat mass, will be replicated to the same or any degree in the PLATEAU Phase 2b study or in any future Phase 3 studies; whether and when the PLATEAU Phase 2b study of enobosarm will produce an interim analysis and/or topline data; whether enobosarm in combination with a GLP-1 RA drug will provide a higher quality and/or greater quantity weight loss in patients and whether this combination therapy will be the next generation drug that makes weight reduction more tissue selective for loss of fat, preservation of lean mass and physical function, improved body composition and maintaining or increasing bone mineral density; whether patients treated with enobosarm in the PLATEAU Phase 2B study will preserve lean mass and physical function leading to an increased use of energy and whether such effects will result in incremental weight reduction; whether patients treated with enobosarm in the PLATEAU Phase 2B study will break through the weight loss plateau and achieve clinically meaningful incremental weight reduction by preserving muscle mass and physical function; and whether the oral form of semaglutide may be used in combination with enobosarm in future Phase 3 clinical studies and whether the injectable semaglutide used in the PLATEAU Phase 2B study data of enobosarm will support the use of oral semaglutide formulation in combination with oral enobosarm in future Phase 3 clinical studies; The words “anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “opportunity,” “plan,” “predict,” “potential,” “estimate,” “should,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based upon current plans and strategies of the Company and reflect the Company’s current assessment of the risks and uncertainties related to its business and are made as of the date of this press release. The Company assumes no obligation to update any forward-looking statements contained in this press release because of new information or future events, developments, or circumstances. Such forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and if any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our actual results could differ materially from those expressed or implied by such statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to: the development of the Company’s product portfolio and the results of clinical studies, including any interim or topline analysis, possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; although the Company has sought and received feedback from the FDA on the designs of its clinical trials and intends to continue to do so, the FDA may ultimately disagree that the Company’s clinical trials support approval; the Company’s ability to reach agreement with FDA on study design requirements for the Company’s planned clinical studies, including for the Phase 2b program for enobosarm as a weight loss or body composition drug and the number of future Phase 3 studies to be required and the cost thereof; potential delays in the timing of and results from clinical trials and studies, including as a result of an inability to enroll sufficient numbers of subjects in clinical studies or an inability to enroll subjects in accordance with planned schedules; the ability to fund planned clinical development as well as other operations of the Company; the Company plans to prioritize the use of its current internal cash to the development of enobosarm, with a primary near-term focus on funding its PLATEAU Phase 2b clinical trial, and as a result advancement of sabizabulin as a treatment for slowing progression of or promoting regression of atherosclerosis disease will depend upon the Company securing additional funding; whether the Company will be able to partner with another company in the development of enobosarm or sabizabulin; the timing of any submission to the FDA or any other regulatory authority and any determinations made by the FDA or any other regulatory authority; the potential for disruptions at the FDA or other government agencies to negatively affect our business, including as a result of a future shutdown of the U.S. government; any products of the Company, if approved, possibly not being commercially successful; the ability of the Company to obtain sufficient financing, including any partnership or collaboration agreements, on acceptable terms when needed to fund development and operations and to enable us to continue as a going concern; the effect of the SEC’s “baby shelf” rules on the Company’s ability to raise sufficient capital when needed; demand for, market acceptance of, and competition against any of the Company’s products or product candidates; new or existing competitors with greater resources and capabilities and new competitive product approvals and/or introductions; changes in regulatory practices or policies or government-driven healthcare reform efforts, including pricing pressures and insurance coverage and reimbursement changes; the Company’s ability to protect and enforce its intellectual property; costs and other effects of litigation, including regulatory challenges, product liability claims, intellectual property, securities litigation and litigation with the purchaser of the Company’s FC2 business; the Company’s ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives; the Company’s ability to successfully integrate acquired businesses, technologies or products; and other risks detailed from time to time in the Company’s press releases, shareholder communications and Securities and Exchange Commission filings, including the Company’s Form 10-K for the year ended September 30, 2025, and subsequent quarterly reports on Form 10-Q. These documents are available on the “SEC Filings” section of our website at www.verupharma.com/investors.

Wegovy® is a registered trademark of Novo Nordisk A/S.

             
FINANCIAL SCHEDULES FOLLOW


 
             
             
Veru Inc.

Condensed Consolidated Balance Sheets

(unaudited)
 
             
    March 31,     September 30,  
    2026     2025  
                 
Cash, cash equivalents, and restricted cash   $ 27,596,820     $ 15,794,562  
Investments in equity securities     3,167,733       2,525,305  
Prepaid expenses and other current assets     2,590,923       595,251  
Total current assets     33,355,476       18,915,118  
                 
Property and equipment, net     308,421       364,808  
Operating lease right-of-use assets     2,479,348       2,746,014  
Goodwill     6,878,932       6,878,932  
Other assets     60,549       930,847  
Total assets   $ 43,082,726     $ 29,835,719  
                 
Accounts payable   $ 2,071,710     $ 3,121,448  
Accrued compensation     2,164,000       3,510,237  
Accrued expenses and other current liabilities     382,876       394,529  
Operating lease liability, short-term portion     770,257       758,946  
Total current liabilities     5,388,843       7,785,160  
                 
Operating lease liability, long-term portion     2,063,089       2,358,018  
Other liabilities     845,173       1,359,871  
Total liabilities     8,297,105       11,503,049  
                 
Total stockholders’ equity     34,785,621       18,332,670  
Total liabilities and stockholders’ equity   $ 43,082,726     $ 29,835,719  

             
Veru Inc.

Condensed Consolidated Statements of Operations

(unaudited)
 
             
    Three Months Ended     Six Months Ended  
    March 31,     March 31,  
    2026     2025     2026     2025  
                                 
Operating expenses:                                
Research and development   $ 3,145,783     $ 3,932,102     $ 4,489,965     $ 9,648,932  
General and administrative     4,073,185       5,164,433       8,153,018       10,391,546  
Total operating expenses     7,218,968       9,096,535       12,642,983       20,040,478  
                                 
Gain on sale of ENTADFI® assets           974,303             1,669,519  
                                 
Operating loss     (7,218,968 )     (8,122,232 )     (12,642,983 )     (18,370,959 )
                                 
Non-operating income:                                
Gain on extinguishment of debt                       8,624,778  
Other non-operating income, net     4,126,418       269,839       4,217,854       83,885  
Total non-operating income     4,126,418       269,839       4,217,854       8,708,663  
                                 
Net loss from continuing operations     (3,092,550 )     (7,852,393 )     (8,425,129 )     (9,662,296 )
Net income (loss) from discontinued operations, net of taxes     351,418       (49,226 )     351,418       (7,184,670 )
Net loss   $ (2,741,132 )   $ (7,901,619 )   $ (8,073,711 )   $ (16,846,966 )
                                 
Net loss from continuing operations per basic and diluted common shares and pre-funded warrants outstanding   $ (0.13 )   $ (0.54 )   $ (0.39 )   $ (0.66 )
Net income (loss) from discontinued operations per basic and diluted common shares and pre-funded warrants outstanding   $ 0.02     $ (0.00 )   $ 0.02     $ (0.49 )
Net loss per basic and diluted common shares and pre-funded warrants outstanding   $ (0.12 )   $ (0.54 )   $ (0.37 )   $ (1.15 )
                                 
Basic and diluted weighted average common shares outstanding     23,050,320       14,638,614       21,655,705       14,638,502  

       
Veru Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)
 
       
    Six Months Ended  
    March 31,  
    2026     2025  
                 
Net loss   $ (8,073,711 )   $ (16,846,966 )
                 
Adjustments to reconcile net loss to net cash used in operating activities     (2,679,386 )     2,525,640  
                 
Changes in operating assets and liabilities     (4,331,318 )     (4,748,124 )
                 
Net cash used in operating activities     (15,084,415 )     (19,069,450 )
                 
Net cash provided by investing activities     3,520,328       18,393,168  
                 
Net cash provided by (used in) financing activities     23,366,345       (4,221,611 )
                 
Net increase (decrease) in cash, cash equivalents, and restricted cash     11,802,258       (4,897,893 )
                 
Cash, cash equivalents and restricted cash at beginning of period     15,794,562       24,916,285  
                 
Cash, cash equivalents and restricted cash at end of period   $ 27,596,820     $ 20,018,392  
                 

Investor and Media Contact:

Samuel Fisch
Executive Director, Investor Relations and Corporate Communications
Email: [email protected]



DevvStream Highlights Southern Energy Renewables’ Hapag-Lloyd LOI for Green Methanol Project Development and Long-Term Offtake and New Environmental Attributes MOU

DevvStream Highlights Southern Energy Renewables’ Hapag-Lloyd LOI for Green Methanol Project Development and Long-Term Offtake and New Environmental Attributes MOU

New MOU expands DevvStream’s role with Southern’s green methanol platform as proposed XCF-Southern-DevvStream combination advances

CALGARY, Alberta–(BUSINESS WIRE)–
DevvStream Corp. (Nasdaq: DEVS) today highlighted Southern Energy Renewables Inc.’s recently announced Letter of Intent with Hapag-Lloyd AG relating to the potential long-term offtake of green methanol from Southern’s planned Louisiana platform, as well as DevvStream’s new Memorandum of Understanding with Southern to advise on environmental attributes associated with Southern’s green methanol projects.

DevvStream believes Southern’s Hapag-Lloyd announcement is an important market signal for green methanol and further supports the viability of Southern’s development platform. Green methanol is expected to play an important role in the decarbonization of hard-to-abate sectors, including maritime transportation, where customers are increasingly seeking scalable renewable fuel alternatives.

Under DevvStream’s new MOU with Southern, DevvStream will upon finalization be appointed as Southern’s environmental asset advisor for environmental attributes arising from or associated with Southern’s green methanol projects and operations. DevvStream expects to advise Southern on the identification, structuring, commercialization, and monetization of potential environmental attributes, including credits, certificates, book-and-claim attributes, incentives, and other environmental value streams.

DevvStream believes this agreement represents an important extension of its opportunity with Southern’s green methanol platform. By helping monetize environmental attributes associated with renewable fuels, DevvStream believes it can support project economics and help reduce the effective cost of adopting renewable and low-carbon fuels.

“Southern’s announced LOI with Hapag-Lloyd is a strong validation point for green methanol and for Southern’s development strategy,” said Sunny Trinh, Chief Executive Officer of DevvStream. “At the same time, our new MOU with Southern gives DevvStream a direct role in helping identify and potentially monetizing the environmental attributes that can make renewable fuel projects more economic and more scalable.”

Mr. Trinh continued, “These developments further support the strategic rationale for the previously announced proposed business combination among XCF Global, Southern Energy Renewables, and DevvStream. We believe the combination is designed to create a public platform across renewable fuels, infrastructure development, and environmental asset monetization.”

The proposed business combination is intended to bring together XCF’s plans for a public-market platform and SAF business, Southern’s green methanol and clean fuels development platform, and DevvStream’s environmental asset monetization capabilities.

Southern’s LOI with Hapag-Lloyd remains preliminary and subject to milestones, definitive documentation, project development requirements, and other conditions. The DevvStream-Southern MOU is subject to the negotiation of definitive agreements and includes non-binding provisions, except as expressly provided therein. The proposed business combination among XCF, Southern, and DevvStream remains subject to customary closing conditions, regulatory and shareholder approvals, and other requirements, and there can be no assurance that the transaction will be completed on the proposed terms or at all.

About DevvStream

DevvStream is a carbon management company focused on the development, investment, sale, and monetization of environmental assets and sustainability-related projects.

Additional Information and Where to Find It

In connection with the proposed business combination transaction among XCF, DevvStream and Southern, XCF will prepare and file relevant materials with the Securities and Exchange Commission (the “SEC”), including a registration statement on Form S-4 that will contain preliminary proxy statements of DevvStream and XCF that also constitutes a prospectus of XCF (the “Proxy Statements/Prospectus”). A definitive proxy statement is expected to be mailed to stockholders of DevvStream and XCF as of a record date to be established for voting on the proposed business combination transaction and other matters as described in the Proxy Statements/Prospectus. DevvStream, XCF and Southern may also file other documents with the SEC and Canadian securities regulatory authorities regarding the proposed transaction. This communication is not a substitute for any proxy statement, registration statement or prospectus, or any other document that DevvStream and Southern (as applicable) may file with the SEC or Canadian securities regulatory authorities in connection with the proposed transaction. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND SECURITY HOLDERS OF DEVVSTREAM ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENTS/PROSPECTUS WHEN IT BECOMES AVAILABLE AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED BY DEVVSTREAM OR SOUTHERN WITH THE SEC OR CANADIAN SECURITIES REGULATORY AUTHORITIES, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, IN CONNECTION WITH THE PROPOSED TRANSACTION, WHEN THEY BECOME AVAILABLE BECAUSE THESE DOCUMENTS CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. DevvStream’s investors and security holders will be able to obtain free copies of the Proxy Statement/Prospectus (when they become available), as well as other filings containing important information about DevvStream, Southern, and other parties to the proposed transaction, without charge through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by (i) XCF will be available free of charge under the tab “Financials” on the “Investors” page of the XCF’s website at https://xcf.global/investor-relations/financials/sec-filings/ or by contacting the XCF’s Investor Relations Department at [email protected] and (ii) DevvStream will be available free of charge under the tab “Financials” on the “Investor Relations” page of DevvStream’s website at www.devvstream.com/investors/ or by contacting DevvStream’s Investor Relations Department at [email protected].

Participants in the Solicitation

DevvStream, Southern, XCF, EEME and their respective directors and certain of their respective executive officers and employees may be deemed to be participants in the solicitation of proxies from DevvStream’s and XCF’s stockholders in connection with the proposed transaction. Information regarding directors and executive officers of (i) XCF is contained in a Current Report on Form 8-K/A, filed with the SEC on October 31, 2025, its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 31, 2026, and in other documents subsequently filed with the SEC and (ii) DevvStream is contained in DevvStream’s proxy statement for its 2025 annual meeting of stockholders, filed with the SEC on November 18, 2025 and in other documents subsequently filed with the SEC. Additional information regarding the participants in the proxy solicitations and a description of their direct or indirect interests, by security holdings or otherwise, will be contained in the Proxy Statement/Prospectus and other relevant materials filed with the SEC (when they become available). These documents can be obtained free of charge from the sources indicated above.

No Offer or Solicitation

This press release is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties, including statements regarding Southern Energy Renewables’ proposed green methanol platform and related LOI with Hapag-Lloyd AG, DevvStream’s anticipated role and activities under the MOU with Southern, the potential identification, structuring, commercialization, and monetization of environmental attributes associated with Southern’s green methanol platform, the potential effect of environmental attribute monetization on renewable fuel project economics, future demand for green methanol and other low-carbon fuels the proposed transactions contemplated by the business combination agreement, the anticipated structure, timing and conditions of the proposed transaction, the anticipated completion of the plant conversion, the achievement of specified financial and operational milestones (including annualized blended fuel product revenues in excess of $1.0 billion and minimum annualized EBITDA of $100 million), and the anticipated issuance of state-supported bonds by Southern, and the valuation the parties are aiming to achieve. All statements, other than statements of historical facts, are forward-looking statements, including: statements regarding the expected timing, structure and terms of the proposed transaction; the ability of the parties to complete the proposed transaction considering the various closing conditions; the expected benefits of the proposed transaction; legal, economic, and regulatory conditions; and any assumptions underlying any of the foregoing. Forward-looking statements concern future circumstances and results and other statements that are not historical facts and are sometimes identified by the words “aim,” “may,” “will,” “should,” “potential,” “intend,” “expect,” “endeavor,” “seek,” “anticipate,” “estimate,” “overestimate,” “underestimate,” “believe,” “plan,” “could,” “would,” “project,” “predict,” “continue,” “target,” “objective,” “goal,” “designed,” or the negatives of these words or other similar terms or expressions that concern XCF’s, DevvStream’s, or Southern’s expectations, strategy, priorities, plans, or intentions. Forward-looking statements are based upon current plans, estimates, expectations, and assumptions that are subject to risks, uncertainties, and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those expressed or implied by such forward-looking statements.

We can give no assurance that such plans, estimates, or expectations will be achieved, and therefore, actual results may differ materially from any plans, estimates, or expectations in such forward-looking statements.

Forward-looking statements are based on current expectations, estimates, assumptions and projections and involve known and unknown risks and uncertainties that may cause actual results, developments or outcomes to differ materially from those expressed or implied by such statements. Important factors that could cause actual results, developments or outcomes to differ materially include, among others: (1) changes in domestic and foreign business, market, financial, political, regulatory and legal conditions; (2) the risk that the plant conversion is delayed, not completed on the anticipated timeline, or requires additional capital beyond current expectations; (3) the risk that XCF is unable to achieve the specified annualized revenue and EBITDA thresholds, which depend in significant part on XCF’s business performance, operating results, market demand, execution capabilities, and other factors; (4) the risk that Southern does not receive authorization to issue up to $400 million of bonds, that such bonds are delayed, issued on less favorable terms, or not issued at all; (5) the risk that XCF is unable to obtain or maintain compliance with applicable Nasdaq continued listing standards, including regaining compliance with $1.00 minimum bid price requirement, which could result in delisting if compliance is not regained within applicable cure periods; (6) the inability to satisfy or waive the closing conditions contemplated by the business combination agreement; (7) the occurrence of events, changes or other circumstances that could give rise to the termination of the business combination agreement, or that could result in disputes or litigation relating to the interpretation, enforceability or performance of the business combination agreement; (8) the outcome of any legal proceedings that may be instituted against XCF, DEVS, Southern, EEME or their respective affiliates, which could be costly, time-consuming, divert management attention and adversely affect liquidity or financial condition; (9) uncertainty with respect to the scope, timing or completion of due diligence by any party and each party’s satisfaction therewith; (10) uncertainty regarding valuations, capital structure, financing arrangements, equity ownership, or the allocation of economic interests contemplated by the business combination agreement, including the risk that, in the event the proposed transaction closes, the parties may never achieve their aim of creating a $3.0 billion combined enterprise (as of the date hereof this statement only represents an objective that the parties intend to achieve on a future date and such objective has not in the past and may never in the future be achieved); (11) changes to the structure, timing or terms of any proposed transaction that may be required or deemed appropriate as a result of applicable laws, regulations, accounting considerations, stock exchange requirements or regulatory guidance; (12) the risk that required regulatory, governmental, stock exchange or shareholder approvals are not obtained, are delayed or are subject to conditions that could adversely affect the parties or the expected benefits of any contemplated transaction; (13) the risk that the announcement of the business combination agreement or the pursuit of the contemplated transactions disrupts current plans, operations or relationships of XCF, DEVS or Southern; (14) the risk that anticipated benefits of any contemplated transaction are not realized due to competition, execution challenges, market conditions, or the inability to grow and manage operations profitably; (15) costs, expenses and management distraction associated with the potential litigation and any contemplated transactions; (16) changes in applicable laws, regulations or enforcement priorities, including extensive regulation and compliance obligations applicable to the parties’ businesses; and (17) other economic, business, competitive, operational or financial factors beyond management’s control, including those set forth in (i) XCF’s filings with the SEC, including the final proxy statement/prospectus relating to the Business Combination filed with the SEC on February 6, 2025, this Press Release and other filings XCF made or will make with the SEC in the future and (ii) DevvStream’s Form 10-K for the fiscal year ended July 31, 2025, filed with the SEC on November 6, 2025, and subsequent reports filed with SEC and Canadian securities regulatory authorities available on DevvStream’s profile at www.sedarplus.ca.

Although the business combination agreement is binding on the parties, it does not obligate the parties to consummate the proposed transaction. The consummation of the proposed transaction remains subject to the satisfaction or waiver of applicable closing conditions, and the business combination agreement may be terminated in accordance with its terms. There can be no assurance that the proposed transaction will be consummated on the terms described herein or at all. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof and are not guarantees of future performance or outcomes.

Any forward-looking statements speak only as of the date of this press release. Neither DevvStream, XCF, Southern or EEME undertakes any obligation to update any forward-looking statements, whether as a result of new information or developments, future events, or otherwise, except as required by law. Neither future distribution of this press release nor the continued availability of this press release in archive form on DevvStream’s website at www.devvstream.com/investors/ or XCF’s website at www.xcf.global/investor-relations should be deemed to constitute an update or re-affirmation of these statements as of any future date.

Investor Relations Contact

DevvStream: [email protected]

XCF: [email protected]

Southern: [email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Sustainability Alternative Energy Energy Environment

MEDIA:

Logo
Logo

Walker & Dunlop Arranges Largest HUD 221(d)(4) in Company History; $130 Million for Former VA Hospital Redevelopment

Walker & Dunlop Arranges Largest HUD 221(d)(4) in Company History; $130 Million for Former VA Hospital Redevelopment

BETHESDA, Md.–(BUSINESS WIRE)–Walker & Dunlop, Inc. announced today that it has arranged $130 million in financing for the redevelopment of a historic former Veterans Affairs (VA) hospital campus into a 493-unit Class A mixed-use community in Denver, Colorado. The financing, executed through the U.S. Department of Housing and Urban Development (HUD) 221(d)(4) loan program, represents the largest 221(d)(4) construction loan in the company’s history.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513926684/en/

Photo Credit: GM Development

Photo Credit: GM Development

Chris Rumul, Jason Silva, Cole Parker, and Mike Valucci of Walker & Dunlop FHA Finance arranged the transaction on behalf of their client, GM Development. The project incorporates historic tax credits as a key component of the capital stack, enabling the adaptive reuse of the long-vacant property.

“Executing the largest HUD 221(d)(4) loan in Walker & Dunlop’s history is a significant milestone for our platform,” said Ken Buchanan, EVP and head of FHA Finance at Walker & Dunlop. “We’re proud to partner with GM Development, The City of Denver, and HUD to transform this historic asset, leveraging the program and historic tax credits to deliver high-quality housing while preserving an important piece of Denver’s history.”

Located at the northwest corner of East 9th Avenue and Clermont Street, the 8.22-acre former VA hospital campus will be redeveloped into a Class A mixed-use community at 1055 North Clermont Street. The project will deliver 493 rental units, primarily market-rate, with approximately 8% designated as income-restricted at 60% AMI, within a restored historic 10-story building and an eight-level parking garage. It will also include more than 50,000 square feet of retail and medical office space, including 43,612 square feet on the first floor and garden level, with 12,594 square feet of frontage along East 9th Avenue opening into a central atrium.

“We’re excited to transform this historic site into a vibrant mixed-use community that will help revitalize the surrounding neighborhood and activate a long-underutilized property,” said Sam Edelson, principal at GM Development. “By preserving and repositioning this landmark asset, we’re creating a place that blends history with modern living. We’re grateful to Walker & Dunlop and HUD for their partnership in bringing this vision to life.”

Situated in Denver’s Hale neighborhood, the property is adjacent to the growing 9+CO master-planned district and directly east of Rose Medical Center. The site benefits from strong connectivity to major thoroughfares, including East Colfax Avenue, and is approximately three miles from downtown Denver and 23 miles from Denver International Airport.

Walker & Dunlop is a leading HUD lender, ranked No. 5 based on MAP (Multifamily Accelerated Processing) and LEAN volume in 2025. Since its inception, the firm’s FHA/HUD platform has closed $45 billion across more than 2,000 transactions and continues to deliver consistent results, with a 99% approval rate since 2021. To learn more about our capabilities and financing solutions, visit our website.

About Walker & Dunlop

Walker & Dunlop (NYSE: WD) is one of the largest commercial real estate finance and advisory services firms in the United States and internationally. Our ideas and capital create communities where people live, work, shop, and play. Our innovative people, breadth of our brand, and our technological capabilities make us one of the most insightful and client-focused firms in the commercial real estate industry.

Investors:

Kelsey Duffey

Investor Relations

Phone 301.202.3207

[email protected]

Media:

Nina H. von Waldegg

Public Relations

Phone 301.564.3291

[email protected]

Phone 301.215.5500

7272 Wisconsin Avenue, Suite 1300

Bethesda, Maryland 20814

KEYWORDS: Maryland United States North America

INDUSTRY KEYWORDS: Professional Services Other Construction & Property Residential Building & Real Estate Commercial Building & Real Estate Finance Construction & Property REIT

MEDIA:

Photo
Photo
Photo Credit: GM Development
Logo
Logo

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

  • Oversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051
  • Two partial responses observed with continued encouraging tolerability in the ongoing Phase 1 dose escalation ACESOT-1051 trial of WEE1 inhibitor APR-1051
  • Additional clinical data from ACESOT-1051 to be provided at the ASCO 2026 Annual Meeting on May 30, 2026
  • $46.5 million in cash and cash equivalents as of March 31, 2026, with anticipated cash runway into Q1 2028

DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

“We are very encouraged by the progress made across both our clinical and corporate priorities during the first quarter of 2026, including two partial responses observed in the ACESOT-1051 trial evaluating APR-1051. One of these has been confirmed at a second imaging assessment and this patient remains on study,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. “These efficacy results, coupled with the encouraging tolerability, support our precision medicine strategy and reinforce the potential of targeted therapies for patients who have limited treatment options. We look forward to presenting an update from ACESOT-1051 at ASCO 2026 and providing additional insight into APR-1051’s emerging clinical profile. The recent $30 million private placement significantly strengthens our balance sheet and enables us to meaningfully expand patient enrollment, generating the clinical data needed to inform the future clinical path for APR-1051. We are grateful for the trust and support of both new and existing investors, whose participation reflects confidence in our development strategy and the potential of our programs.”

Key Business Updates and Upcoming Key Milestones

ACESOT-1051: A Biomarker Focused, Phase 1 Trial of Oral WEE1 inhibitor, APR-1051

  • APR-1051 is a potent and selective, oral small molecule WEE1 inhibitor designed to potentially address therapeutic window limitations observed with earlier WEE1 programs. APR-1051 is being evaluated as monotherapy in uterine serous carcinoma patients regardless of mutation, cyclin E-overexpressing platinum-resistant ovarian cancer, advanced solid tumors harboring CCNE1, CCNE2, PPP2R1A or FBXW7 mutations, colorectal cancer harboring KRAS & TP53 mutations and HPV+ head and neck squamous cell carcinoma. These patient populations are associated with poor prognosis and limited effective treatment options.
  • To date, two patients in ACESOT-1051 have achieved partial responses (“PR”). One uterine carcinosarcoma patient with PPP2R1A-mutation treated at the 220 mg dose level achieved a 50% reduction in target lesion size per RECIST v1.1 criteria and a significant reduction in CA-125 levels at the first imaging assessment. At the confirmatory, second imaging assessment, an additional 9.5% reduction in target lesion size was observed, along with a further decline in CA-125 to 40.2 U/mL from 362 U/mL at baseline. This patient remains on study with an ongoing PR. There has also been an unconfirmed PR in a second patient with PPP2R1A-mutated uterine serous carcinoma, treated at the 150 mg dose level.
  • A total of 28 patients have been treated in ACESOT-1051 to date at doses ranging from 10 mg to 300 mg once daily. Six patients have achieved best overall response of stable disease, including patients with colorectal cancer, HPV+ head and neck squamous cell carcinoma, and endometrial cancer.
  • Dose escalation is ongoing with enrollment currently underway in the 300 mg cohort (dose level 9). Additional eligible patients will be backfilled at 220 mg to further characterize safety, tolerability, and clinical activity, once dose level 9 is fully enrolled.
  • APR-1051 has been shown to be well tolerated; the two most common adverse events have been Grade 1 or 2 nausea and fatigue. No treatment-related class-limiting toxicities, including severe myelosuppression or severe gastrointestinal toxicity, have been observed to date.
  • Supported by the $30 million financing that closed on March 31, 2026, Aprea is expanding enrollment in ACESOT-1051 to include at least 50 patients with uterine serous carcinoma (USC), as well as patients with cyclin E-overexpressing, platinum-resistant ovarian cancer (PROC). The expansion is intended to provide additional safety, tolerability and preliminary efficacy data to inform the future clinical path for APR-1051. Completion of dose escalation is anticipated in the second quarter of 2027.
  • Further clinical updates from ACESOT-1051 are expected during Q2 2026. An abstract entitled “Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)” has been accepted for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The poster will be presented on May 30, 2026, 1:30 – 4:30pm CT.
  • For more information on ACESOT-1051, refer to ClinicalTrials.gov NCT06260514.

ABOYA-119: Clinical Trial Evaluating ATR inhibitor, ATRN-119

  • ATRN-119 is a potent and highly selective first-in-class macrocyclic ATR inhibitor, designed and developed to be used in patients with tumors harboring mutations in DDR-related genes. Cancers with mutations in DDR-related genes represent a high unmet medical need. These patients often have a poor prognosis and currently lack effective therapeutics options.
  • During 2025 Aprea established 1,100 mg once daily as the recommended Phase 2 dose (RP2D) in the ABOYA-119 clinical trial. The Company strategically paused further enrollment and has started an orderly wind-down of certain clinical trial site activities associated with the monotherapy, as the Company explores ATRN-119 in potential combination approaches that may unlock greater clinical benefit. The Company is currently in discussions with leading academic institutions to evaluate ATRN-119 in combination with radiation in HPV+ head and neck cancer. Additional investigator-led studies evaluating ATRN-119 with immuno-oncology therapies and antibody-drug conjugates are also being explored.
  • For more information on ABOYA-119, please refer to clinicaltrials.gov NCT04905914.

Corporate

  • On March 31, 2026, the Company closed an oversubscribed private placement, raising gross proceeds of $30 million. The private placement was led by Soleus Capital with participation from other new investors, including Vestal Point Capital and Squadron Capital Management, existing investors and certain insiders of the Company. Net proceeds will be used for general corporate purposes and research and development expenses, including the addition of more patients with USC (regardless of mutation status) into the ACESOT-1051 study and expansion into cyclin E-overexpressing PROC patients.
  • In February 2026, the Company appointed Eugene (Gene) Kennedy, MD, as Chief Medical Advisor. Dr. Kennedy is a highly accomplished physician scientist and biopharmaceutical executive with more than 20 years of experience spanning oncology clinical development, regulatory strategy, and senior corporate leadership across public and private biotechnology companies.

Select Financial Results for the First Quarter Ended March 31, 2026

As of March 31, 2026, the Company reported cash and cash equivalents of $46.5 million compared to $14.6 million as of December 31, 2025. The Company believes that its cash and cash equivalents as of March 31, 2026 will be sufficient to meet its currently projected operating expenses and capital expenditure requirements into the first quarter of 2028.

For the first quarter ended March 31, 2026, the Company reported an operating loss of $3.4 million, compared to an operating loss of $4.1 million in the first quarter of 2025.

Research and Development (R&D) expenses were $1.6 million for the quarter ended March 31, 2026, compared to $2.5 million for the first quarter of 2025. The decrease in R&D expense was primarily related to a decrease of $0.8 million related to the ABOYA-119 clinical trial to evaluate ATRN-119, our clinical-stage oral small molecule inhibitor of ATR, which was voluntarily paused in October 2025.

General and Administrative (G&A) expenses were $1.8 million for each of the quarters ended March 31, 2026 and 2025.

The Company reported a net loss of $3.3 million or ($0.22) loss per basic share on approximately 14.7 million weighted-average common shares outstanding for the quarter ended March 31, 2026, compared to a net loss of $3.9 million ($0.66) per basic share on approximately 6.0 million weighted average common shares outstanding for the comparable period in 2025.

About Aprea

Aprea is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The Company is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors while minimizing the effect on normal, healthy cells. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma. The Company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For more information, please visit the Company website at www.aprea.com.

The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statement

Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs, and our ability to predict clinical outcomes based on such preclinical and early clinical results, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.

Investor Contact:
Mike Moyer
LifeSci Advisors
[email protected]

 
Aprea Therapeutics, Inc.
Consolidated Balance Sheets
           
       
  March 31, 2026   December 31, 2025
Assets (unaudited)      
Current assets:          
Cash and cash equivalents $ 46,466,202     $ 14,599,347  
Prepaid expenses and other current assets   779,238       961,899  
Total current assets   47,245,440       15,561,246  
Property and equipment, net   54,379       59,807  
Restricted cash   41,406       41,186  
Other noncurrent assets   271,162       271,162  
Total assets $ 47,612,387     $ 15,933,401  
Liabilities and Stockholders’ Equity          
Current liabilities:          
Accounts payable $ 2,940,756     $ 713,668  
Accrued expenses   2,355,890       2,050,690  
Total current liabilities   5,296,646       2,764,358  
Commitments and contingencies          
Series A convertible preferred stock, $0.001 par value, 40,000,000 shares authorized; 31,194 shares issued and outstanding at March 31, 2026 and December 31, 2025   727,361       727,361  
Stockholders’ equity:          
Common stock, $0.001 par value, 400,000,000 shares authorized, 11,982,776 and 8,192,538 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively   11,983       8,192  
Additional paid-in capital   389,631,454       356,709,645  
Subscription Receivable   (499,999 )      
Accumulated other comprehensive loss   (10,625,700 )     (10,634,714 )
Accumulated deficit   (336,929,358 )     (333,641,441 )
Total stockholders’ equity   41,588,380       12,441,682  
Total liabilities and stockholders’ equity $ 47,612,387     $ 15,933,401  
           

Aprea Therapeutics, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
           
  Three Months Ended March 31,
  2026   2025
Grant revenue $     $ 162,463  
Operating expenses:          
Research and development   1,611,167       2,483,066  
General and administrative   1,819,245       1,764,979  
Total operating expenses   3,430,412       4,248,045  
Loss from operations   (3,430,412 )     (4,085,582 )
Other income (expense):          
Interest income, net   134,784       204,726  
Foreign currency gain (loss)   7,711       (51,803 )
Total other income   142,495       152,923  
Net loss $ (3,287,917 )   $ (3,932,659 )
Other comprehensive loss:          
Foreign currency translation   9,014       643  
Total comprehensive loss $ (3,278,903 )   $ (3,932,016 )
Net loss per share attributable to common stockholders, basic and diluted $ (0.22 )   $ (0.66 )
Weighted-average common shares outstanding, basic and diluted   14,685,448       5,993,866  
           



Dynatrace Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results

Dynatrace Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results

Surpasses $2 billion in ARR and reports double digit net new ARR growth

Delivers fourth consecutive quarter of 16% ARR growth on a constant currency basis

Achieves FY26 GAAP Operating Margin of 12% and Non-GAAP Operating Margin of 29%

Increases Q4 share repurchases sequentially by 40% to $224 million

BOSTON–(BUSINESS WIRE)–
Dynatrace (NYSE: DT), the leading AI-powered observability platform, today announced financial results for the fourth quarter and full year ended March 31, 2026.

“Dynatrace delivered a strong finish to FY26, surpassing $2 billion in ARR and achieving our fourth consecutive quarter of 16% constant currency ARR growth,” said Rick McConnell, CEO of Dynatrace. “In an AI‑first world, observability has become mission critical to a vastly higher percentage of workloads. Customers are choosing Dynatrace for our end‑to‑end platform, which serves as both the intelligence engine for deterministic AI and contextual analytics, as well as the control plane to coordinate agentic action. By enabling system resilience and AI reliability, Dynatrace is helping customers drive more autonomous operations and optimal business outcomes. As we look ahead, our objective is to accelerate ARR growth while delivering balanced growth and profitability.”

“We significantly increased the pace of our share buyback in the fourth quarter, repurchasing $224 million of Dynatrace stock,” said Jim Benson, Chief Financial Officer. “This uptick reflects our conviction in Dynatrace’s operational momentum, long term growth and cash flow trajectory, and the underlying value of our shares. Through our disciplined capital allocation approach and strong balance sheet, we will continue investing in innovation and growth while delivering value to shareholders.”

All growth rates are compared to the fourth quarter and full year fiscal 2025 ended March 31, 2025 unless otherwise noted.

Fourth Quarter Fiscal 2026 Financial Highlights:

  • Total ARR of $2,054 million, an increase of 18%, or 16% on a constant currency basis

  • Total revenue of $532 million, an increase of 19%, or 16% on a constant currency basis

  • Subscription revenue of $506 million, an increase of 19%, or 16% on a constant currency basis

  • GAAP income from operations of $37 million and non-GAAP income from operations of $143 million

  • GAAP net income per share of $0.06 and non-GAAP net income per share of $0.41, on a dilutive basis

Full Year Fiscal 2026 Financial Highlights:

  • Total revenue of $2,018 million, an increase of 19%, or 17% on a constant currency basis

  • Subscription revenue of $1,930 million, an increase of 19%, or 17% on a constant currency basis

  • GAAP income from operations of $245 million and non-GAAP income from operations of $592 million

  • GAAP net income per share of $0.54 and non-GAAP net income per share of $1.70, on a dilutive basis

  • GAAP operating cash flow of $562 million and free cash flow of $529 million

Business Highlights:

  • Ongoing traction in go-to-market strategy resulted in an increase in average deal size. Dynatrace closed a record 22 deals greater than $1 million in annual contract value (ACV) in the fourth quarter, nine of which were new logos.

  • Log management remained the fastest growing major product category, with Q4 consumption continuing to grow more than 100% year-over-year.

  • Enhanced the company’s offerings through two acquisitions:

    • DevCycle, a feature management platform on the OpenFeature standard that helps developers, site reliability engineers, and platform teams bring progressive delivery for AI-native applications directly into the Dynatrace platform.
    • Bindplane, a company whose open-standards-based telemetry pipeline capabilities combined with AI-powered observability gives customers greater access, flexibility, and control of their logs, metrics, and application data.
  • Surpassed $1 billion in AWS Marketplace sales, a key indicator of hyperscaler engagement.

  • Expanded the Dynatrace Model Context Protocol (MCP) server as a connector for Anthropic’s Claude Code, Cowork, and Chat to bring observability and security context into every Claude session. And extended integration with GitHub Advanced Security to share the runtime context of monitored Kubernetes environments with developers and security teams.

  • Recognized as a Customers’ Choice in the 2025 Gartner Peer Insights Voice of the Customer for Observability Platforms report.1

Share Repurchase Program

  • During the fourth quarter of fiscal 2026, Dynatrace spent $224 million to repurchase 5.9 million shares at an average price of $37.71. Dynatrace completed its initial $500 million share repurchase program, and $151 million of purchases in the fourth quarter were under its new $1 billion program announced in February 2026.

Fourth Quarter 2026 Financial Highlights

(Unaudited – In thousands, except per share data)

 

 

Three Months Ended March 31,

 

 

2026

 

 

 

2025

 

Annual recurring revenue (ARR):

 

 

 

Total ARR

$

2,053,555

 

 

$

1,734,164

 

Year-over-Year Increase

 

18

%

 

 

Year-over-Year Increase – constant currency (*)

 

16

%

 

 

 

 

 

 

Revenue:

 

 

 

Total revenue

$

531,716

 

 

$

445,165

 

Year-over-Year Increase

 

19

%

 

 

Year-over-Year Increase – constant currency (*)

 

16

%

 

 

 

 

 

 

Subscription revenue

$

505,754

 

 

$

423,570

 

Year-over-Year Increase

 

19

%

 

 

Year-over-Year Increase – constant currency (*)

 

16

%

 

 

 

 

 

 

GAAP Financial Measures:

 

 

 

GAAP income from operations

$

37,342

 

 

$

42,914

 

GAAP operating margin

 

7

%

 

 

10

%

 

 

 

 

GAAP net income

$

17,416

 

 

$

39,304

 

 

 

 

 

GAAP net income per share – diluted

$

0.06

 

 

$

0.13

 

 

 

 

 

GAAP shares outstanding – diluted

 

298,925

 

 

 

304,354

 

 

 

 

 

Net cash provided by operating activities

$

226,361

 

 

$

162,790

 

Net cash provided by operating activities as a percent of revenue

 

43

%

 

 

37

%

 

 

 

 

Non-GAAP Financial Measures (*):

 

 

 

Non-GAAP income from operations

$

142,576

 

 

$

117,887

 

Non-GAAP operating margin

 

27

%

 

 

26

%

 

 

 

 

Non-GAAP net income

$

123,967

 

 

$

99,047

 

 

 

 

 

Non-GAAP net income per share – diluted

$

0.41

 

 

$

0.33

 

 

 

 

 

Non-GAAP shares outstanding – diluted

 

298,925

 

 

 

304,354

 

 

 

 

 

Free Cash Flow

$

212,403

 

 

$

145,528

 

Free Cash Flow margin

 

40

%

 

 

33

%

Full Year 2026 Financial Highlights

(Unaudited – In thousands, except per share data)

 

 

Year Ended March 31,

 

 

2026

 

 

 

2025

 

Revenue:

 

 

 

Total revenue

$

2,018,387

 

 

$

1,698,683

 

Year-over-Year Increase

 

19

%

 

 

Year-over-Year Increase – constant currency (*)

 

17

%

 

 

 

 

 

 

Subscription revenue

$

1,929,722

 

 

$

1,622,163

 

Year-over-Year Increase

 

19

%

 

 

Year-over-Year Increase – constant currency (*)

 

17

%

 

 

 

 

 

 

GAAP Financial Measures:

 

 

 

GAAP income from operations

$

245,387

 

 

$

179,433

 

GAAP operating margin

 

12

%

 

 

11

%

 

 

 

 

GAAP net income (**)

$

162,669

 

 

$

483,684

 

 

 

 

 

GAAP net income per share – diluted (**)

$

0.54

 

 

$

1.59

 

 

 

 

 

GAAP shares outstanding – diluted

 

303,727

 

 

 

303,602

 

 

 

 

 

Net cash provided by operating activities

$

561,850

 

 

$

459,419

 

Net cash provided by operating activities as a percent of revenue

 

28

%

 

 

27

%

 

 

 

 

Non-GAAP Financial Measures (*):

 

 

 

Non-GAAP income from operations

$

591,929

 

 

$

493,540

 

Non-GAAP operating margin

 

29

%

 

 

29

%

 

 

 

 

Non-GAAP net income

$

517,641

 

 

$

422,313

 

 

 

 

 

Non-GAAP net income per share – diluted

$

1.70

 

 

$

1.39

 

 

 

 

 

Non-GAAP shares outstanding – diluted

 

303,727

 

 

 

303,602

 

 

 

 

 

Free Cash Flow

$

529,483

 

 

$

430,617

 

Free Cash Flow margin

 

26

%

 

 

25

%

 

* For additional information, please see the “Non-GAAP Financial Measures” and “Definitions – Non-GAAP and Other Metrics” sections of this press release.

 

** During fiscal 2025, Dynatrace completed an intra-entity asset transfer of the global economic rights of intellectual property (IP) from a wholly-owned U.S. subsidiary to a wholly-owned Swiss subsidiary, more closely aligning IP rights with business operations. The transfer generated an income tax benefit of $320.9 million, or $1.06 per share on a dilutive basis.

Financial Outlook

Based on information available as of May 13, 2026, Dynatrace is issuing guidance for the first quarter and full year fiscal 2027 in the table below. Based on foreign exchange rates as of April 30, 2026, the foreign exchange tailwind relative to constant currency is expected to be approximately $10 million on ARR and $15 million on revenue for fiscal 2027. This guidance also excludes the impact of any share repurchases during fiscal 2027.

Growth rates for ARR, Total revenue, and Subscription revenue are presented in constant currency to provide better visibility into the underlying growth of the business.

All growth rates are compared to the first quarter and full year of fiscal 2026 ended March 31, 2026 unless otherwise noted.

 

(In millions, except per share data)

First Quarter

Fiscal 2027

 

Full Year

Fiscal 2027

ARR

 

$2,382 – $2,402

As reported

 

16% – 17%

Constant currency

 

15.5% – 16.5%

Total revenue

$547 – $551

 

$2,317 – $2,335

As reported

15%

 

15% – 16%

Constant currency

13% – 14%

 

14% – 15%

Subscription revenue

$523 – $527

 

$2,217 – $2,235

As reported

14% – 15%

 

15% – 16%

Constant currency

13% – 14%

 

14% – 15%

Non-GAAP income from operations

$150 – $154

 

$682 – $690

Non-GAAP operating margin

27.5% – 28%

 

29.5%

Non-GAAP net income

$130 – $134

 

$584 – $594

Non-GAAP net income per diluted share

$0.44 – $0.45

 

$1.93 – $1.95

Diluted weighted average shares outstanding

298 – 299

 

302 – 304

Free cash flow

 

$613 – $620

Free cash flow margin

 

26.5%

Conference Call and Webcast Information

Dynatrace will host a conference call and live webcast to discuss its results and business outlook at 8:00 a.m. Eastern Time today, May 13, 2026. To access the conference call from the U.S. and Canada, dial (866) 405-1247, or internationally, dial (201) 689-8045 with event confirmation #: 13760309. The call will also be available live via webcast on the company’s website, ir.dynatrace.com.

An audio replay of the call will also be available until 11:59 p.m. Eastern Time on August 13, 2026 by dialing (877) 660-6853 from the U.S. or Canada, or for international callers by dialing (201) 612-7415 and entering event confirmation #: 13760309. In addition, an archived webcast will be available at ir.dynatrace.com.

We announce material financial information to our investors using our Investor Relations website, press releases, SEC filings and public conference calls and webcasts. We also use these channels to disclose information about the company, our planned financial and other announcements, attendance at upcoming investor and industry conferences, and for complying with our disclosure obligations under Regulation FD.

Non-GAAP Financial Measures

In addition to disclosing financial measures prepared in accordance with GAAP, this press release and the accompanying tables contain certain non-GAAP financial measures as defined by Regulation G, including non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income, non-GAAP net income per diluted share, free cash flow, and free cash flow margin. We also use or discuss non-GAAP financial measures in conference calls, slide presentations and webcasts.

We use these non-GAAP financial measures for financial and operational decision-making purposes, and as a means to evaluate period-to-period comparisons and liquidity. We believe that these non-GAAP financial measures provide useful information about our operating results, enhance the overall understanding of past financial performance and allow for greater transparency with respect to metrics used by our management in its financial and operational decision-making.

The presentation of the non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. Our non-GAAP financial measures may not provide information that is directly comparable to similarly titled metrics provided by other companies.

Non-GAAP financial measures are defined in this press release and the tables included in this press release include reconciliations of historical non-GAAP financial measures to their most directly comparable GAAP measures.

We also include non-GAAP financial measures in our financial outlook included in this press release. Reconciliations of forward-looking non-GAAP income from operations, non-GAAP net income, non-GAAP net income per diluted share, and free cash flow guidance to the most directly comparable GAAP measures are not available without unreasonable efforts due to the high variability, complexity, and low visibility with respect to the charges excluded from these non-GAAP measures; in particular, the measures and effects of share-based compensation expense, employer taxes and tax deductions specific to equity compensation awards that are directly impacted by future hiring, turnover and retention needs, as well as unpredictable fluctuations in our stock price. We expect the variability of the above charges to have a significant, and potentially unpredictable, impact on our future GAAP financial results.

Definitions – Non-GAAP and Other Metrics

Annual Recurring Revenue (ARR) is defined as the daily revenue of all subscription agreements that are actively generating revenue as of the last day of the reporting period multiplied by 365. We exclude from our calculation of ARR any revenues derived from month-to-month agreements and/or product usage overage billings.

Constant Currency amounts for ARR, Total revenue, and Subscription revenue are presented to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign exchange rate fluctuations. To present this information, current and comparative prior period results for entities reporting in currencies other than United States dollars are converted into United States dollars using the average exchange rates from the comparative period rather than the actual exchange rates in effect during the respective periods. All growth comparisons relate to the corresponding period in the last fiscal year.

Non-GAAP Income from Operations is defined as GAAP income from operations adjusted for the following items: share-based compensation; employer payroll taxes on employee stock transactions; amortization of intangibles; transaction, restructuring and other non-recurring or unusual items that may arise from time to time. The related Non-GAAP Operating Margin is non-GAAP income from operations expressed as a percentage of total revenue.

Non-GAAP Net Income is defined as GAAP net income adjusted for the following items: income tax expense/benefit; non-GAAP effective cash taxes; net interest expense and income; net cash received from and paid for interest; share-based compensation; employer payroll taxes on employee stock transactions, amortization of intangibles; gains and losses on currency translation; and transaction, restructuring and other non-recurring or unusual items that may arise from time to time. Non-GAAP net income per diluted share is calculated as non-GAAP net income divided by the diluted weighted average shares outstanding used to compute GAAP net income per diluted share.

Free Cash Flow is defined as the net cash provided by or used in operating activities less capital expenditures, reflected as purchase of property and equipment and capitalized software additions in our financial statements. The related margin is free cash flow expressed as a percentage of total revenue.

About Dynatrace

Dynatrace (NYSE: DT) is advancing observability for today’s digital businesses, helping to transform the complexity of modern digital ecosystems into powerful business assets. By leveraging AI-powered insights, Dynatrace enables organizations to analyze, automate, and innovate faster to drive their business forward. To learn more about Dynatrace, visit www.dynatrace.com, visit our blog and follow us on LinkedIn and X @dynatrace.

Dynatrace and the Dynatrace logo are trademarks of the Dynatrace, Inc. group of companies. All other trademarks are the property of their respective owners. © 2026 Dynatrace LLC.

Cautionary Language Concerning Forward-Looking Statements

This press release includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s objective to accelerate ARR growth while delivering balanced growth and profitability, the company’s plans to invest in innovation and growth while delivering value to shareholders, the expected and current benefits that we believe organizations receive from using the Dynatrace platform and offerings of our partners and other companies with which we collaborate and integrate, and our financial and business outlook, including our financial guidance for the first quarter and full year of fiscal 2027. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions and other statements contained in this press release that are not historical facts and statements identified by words such as “will,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” or words of similar meaning. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, our ability to maintain our revenue growth rates in future periods; market adoption of our product offerings; continued demand for, and spending on, our solutions; our ability to innovate and develop solutions that meet customer needs as cloud and AI workloads grow rapidly; the ability of our platform and solutions to effectively interoperate with customers’ IT infrastructures; our ability to acquire new customers and retain and expand our relationships with existing customers; our ability to expand our sales and marketing capabilities; our ability to compete; our ability to maintain successful relationships with partners; security breaches, other security incidents and any real or perceived errors, failures, defects or vulnerabilities in our solutions; our ability to protect our intellectual property; our ability to hire and retain necessary qualified employees to grow our business and expand our operations; our ability to successfully complete acquisitions and to integrate newly acquired businesses and offerings; the effect on our business of the macroeconomic environment, associated global economic conditions and geopolitical disruption; and other risks set forth under the caption “Risk Factors” in our Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, and our other SEC filings. We assume no obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

____________________

Gartner Disclaimers

1Gartner, Voice of the Customer for Observability Platforms, Peer Community Contributors, 24 December 2025.

 

GARTNER and PEER INSIGHTS™ are trademarks of Gartner, Inc. and/or its affiliates. All rights reserved.

 

Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

 

The Gartner content described herein (the “Gartner Content”) represents research opinion or viewpoints published, as part of a syndicated subscription service, by Gartner, Inc. (“Gartner”), and is not a representation of fact. Gartner Content speaks as of its original publication date (and not as of the date of this Earnings Press Release), and the opinions expressed in the Gartner Content are subject to change without notice.

DYNATRACE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited – In thousands, except per share data)

 

 

Three Months Ended March 31,

 

Twelve Months Ended March 31,

 

 

2026

 

 

 

2025

 

 

 

2026

 

 

 

2025

 

Revenue:

 

 

 

 

 

 

 

Subscription

$

505,754

 

 

$

423,570

 

 

$

1,929,722

 

 

$

1,622,163

 

Service

 

25,962

 

 

 

21,595

 

 

 

88,665

 

 

 

76,520

 

Total revenue

 

531,716

 

 

 

445,165

 

 

 

2,018,387

 

 

 

1,698,683

 

Cost of revenue:

 

 

 

 

 

 

 

Cost of subscription

 

77,356

 

 

 

63,265

 

 

 

284,611

 

 

 

233,299

 

Cost of service

 

23,112

 

 

 

21,095

 

 

 

84,105

 

 

 

73,631

 

Amortization of acquired technology

 

927

 

 

 

734

 

 

 

3,488

 

 

 

13,262

 

Total cost of revenue

 

101,395

 

 

 

85,094

 

 

 

372,204

 

 

 

320,192

 

Gross profit

 

430,321

 

 

 

360,071

 

 

 

1,646,183

 

 

 

1,378,491

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

Research and development

 

130,579

 

 

 

103,285

 

 

 

474,312

 

 

 

384,572

 

Sales and marketing

 

183,442

 

 

 

161,797

 

 

 

690,489

 

 

 

605,599

 

General and administrative

 

60,413

 

 

 

52,062

 

 

 

217,414

 

 

 

195,347

 

Amortization of other intangibles

 

20

 

 

 

13

 

 

 

56

 

 

 

13,540

 

Impairment of long-lived assets

 

18,525

 

 

 

 

 

 

18,525

 

 

 

 

Total operating expenses

 

392,979

 

 

 

317,157

 

 

 

1,400,796

 

 

 

1,199,058

 

Income from operations

 

37,342

 

 

 

42,914

 

 

 

245,387

 

 

 

179,433

 

Interest income, net

 

10,111

 

 

 

10,930

 

 

 

47,731

 

 

 

48,281

 

Other (expense) income, net

 

(638

)

 

 

1,860

 

 

 

6,643

 

 

 

(4,285

)

Income before income taxes

 

46,815

 

 

 

55,704

 

 

 

299,761

 

 

 

223,429

 

Income tax (expense) benefit

 

(29,399

)

 

 

(16,400

)

 

 

(137,092

)

 

 

260,255

 

Net income

$

17,416

 

 

$

39,304

 

 

$

162,669

 

 

$

483,684

 

Net income per share:

 

 

 

 

 

 

 

Basic

$

0.06

 

 

$

0.13

 

 

$

0.54

 

 

$

1.62

 

Diluted

$

0.06

 

 

$

0.13

 

 

$

0.54

 

 

$

1.59

 

Weighted average shares outstanding:

 

 

 

 

 

 

 

Basic

 

297,544

 

 

 

299,441

 

 

 

300,102

 

 

 

298,384

 

Diluted

 

298,925

 

 

 

304,354

 

 

 

303,727

 

 

 

303,602

 

SHARE-BASED COMPENSATION

 

 

Three Months Ended March 31,

 

Twelve Months Ended March 31,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

Cost of revenue

$

9,619

 

$

9,659

 

$

40,276

 

$

36,924

Research and development

 

28,371

 

 

26,097

 

 

114,110

 

 

100,866

Sales and marketing

 

19,987

 

 

19,855

 

 

84,480

 

 

77,336

General and administrative

 

15,022

 

 

14,593

 

 

60,760

 

 

56,577

Total share-based compensation expense

$

72,999

 

$

70,204

 

$

299,626

 

$

271,703

DYNATRACE, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited – In thousands, except share data)

 

 

March 31,

 

 

2026

 

 

 

2025

 

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

1,097,220

 

 

$

1,017,039

 

Short-term marketable securities

 

74,881

 

 

 

96,189

 

Accounts receivable, net

 

710,200

 

 

 

624,437

 

Deferred contract costs, current

 

127,495

 

 

 

109,895

 

Prepaid expenses and other current assets

 

113,651

 

 

 

83,901

 

Total current assets

 

2,123,447

 

 

 

1,931,461

 

Long-term marketable securities

 

51,908

 

 

 

51,648

 

Property and equipment, net

 

72,993

 

 

 

61,522

 

Operating lease right-of-use asset, net

 

139,285

 

 

 

67,479

 

Goodwill

 

1,350,256

 

 

 

1,336,435

 

Intangible assets, net

 

22,850

 

 

 

25,534

 

Deferred tax assets, net

 

508,742

 

 

 

529,550

 

Deferred contract costs, non-current

 

113,111

 

 

 

95,297

 

Other assets

 

33,133

 

 

 

40,752

 

Total assets

$

4,415,725

 

 

$

4,139,678

 

 

 

 

 

Liabilities and shareholders’ equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

2,728

 

 

$

27,286

 

Accrued expenses, current

 

302,260

 

 

 

252,503

 

Deferred revenue, current

 

1,241,488

 

 

 

1,087,518

 

Operating lease liabilities, current

 

22,588

 

 

 

13,979

 

Total current liabilities

 

1,569,064

 

 

 

1,381,286

 

Deferred revenue, non-current

 

53,387

 

 

 

50,989

 

Accrued expenses, non-current

 

38,205

 

 

 

24,452

 

Operating lease liabilities, non-current

 

141,736

 

 

 

61,384

 

Deferred tax liabilities

 

1,943

 

 

 

419

 

Total liabilities

 

1,804,335

 

 

 

1,518,530

 

Shareholders’ equity:

 

 

 

Common shares, $0.001 par value, 600,000,000 shares authorized, 294,652,951 and 299,813,048 shares issued and outstanding at March 31, 2026 and 2025, respectively

 

295

 

 

 

300

 

Additional paid-in capital

 

2,199,494

 

 

 

2,370,563

 

Retained earnings

 

447,596

 

 

 

284,927

 

Accumulated other comprehensive loss

 

(35,995

)

 

 

(34,642

)

Total shareholders’ equity

 

2,611,390

 

 

 

2,621,148

 

Total liabilities and shareholders’ equity

$

4,415,725

 

 

$

4,139,678

 

DYNATRACE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited – In thousands)

 

 

Three Months Ended March 31,

Twelve Months Ended March 31,

 

 

2026

 

 

 

2025

 

 

2026

 

 

 

2025

 

Cash flows from operating activities:

 

 

 

 

 

 

Net income

$

17,416

 

 

$

39,304

 

$

162,669

 

 

$

483,684

 

Adjustments to reconcile net income to cash provided by operations:

 

 

 

 

 

 

Depreciation

 

4,702

 

 

 

5,385

 

 

18,446

 

 

 

19,236

 

Amortization

 

1,462

 

 

 

1,265

 

 

5,613

 

 

 

28,868

 

Share-based compensation

 

72,999

 

 

 

70,204

 

 

299,626

 

 

 

271,703

 

Deferred income taxes

 

6,658

 

 

 

(14,147

)

 

25,132

 

 

 

(392,942

)

Impairment of long-lived assets

 

18,525

 

 

 

 

 

18,525

 

 

 

 

Other

 

989

 

 

 

(2,100

)

 

(6,928

)

 

 

2,035

 

Net change in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

(245,159

)

 

 

(228,277

)

 

(77,127

)

 

 

(24,026

)

Deferred contract costs

 

(7,203

)

 

 

(11,613

)

 

(31,057

)

 

 

(14,648

)

Prepaid expenses and other assets

 

(24,981

)

 

 

(15,020

)

 

(15,977

)

 

 

(36,593

)

Accounts payable and accrued expenses

 

56,344

 

 

 

59,142

 

 

25,896

 

 

 

31,534

 

Operating leases, net

 

978

 

 

 

(665

)

 

2,434

 

 

 

(231

)

Deferred revenue

 

323,631

 

 

 

259,312

 

 

134,598

 

 

 

90,799

 

Net cash provided by operating activities

 

226,361

 

 

 

162,790

 

 

561,850

 

 

 

459,419

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

Purchase of property and equipment

 

(13,958

)

 

 

(14,566

)

 

(32,173

)

 

 

(26,106

)

Capitalized software additions

 

 

 

 

(2,696

)

 

(194

)

 

 

(2,696

)

Acquisition of businesses, net of cash acquired

 

(6,000

)

 

 

 

 

(6,000

)

 

 

(100

)

Purchases of marketable securities

 

(11,448

)

 

 

(37,566

)

 

(120,306

)

 

 

(145,555

)

Proceeds from sales and maturities of marketable securities

 

39,847

 

 

 

36,997

 

 

143,729

 

 

 

105,142

 

Other

 

(750

)

 

 

 

 

(750

)

 

 

 

Net cash provided by (used in) investing activity

 

7,691

 

 

 

(17,831

)

 

(15,694

)

 

 

(69,315

)

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

Proceeds from employee stock purchase plan

 

 

 

 

 

 

24,390

 

 

 

21,159

 

Proceeds from exercise of stock options

 

1,786

 

 

 

6,092

 

 

6,487

 

 

 

20,995

 

Repurchases of common stock

 

(223,675

)

 

 

(42,518

)

 

(478,708

)

 

 

(172,618

)

Taxes paid related to net share settlement of equity awards

 

(2,211

)

 

 

(2,620

)

 

(21,845

)

 

 

(18,958

)

Other

 

(552

)

 

 

(552

)

 

(4,418

)

 

 

(2,208

)

Net cash used in financing activities

 

(224,652

)

 

 

(39,598

)

 

(474,094

)

 

 

(151,630

)

 

 

 

 

 

 

 

Effect of exchange rates on cash and cash equivalents

 

(3,714

)

 

 

4,196

 

 

8,119

 

 

 

(418

)

 

 

 

 

 

 

 

Net increase in cash and cash equivalents

 

5,686

 

 

 

109,557

 

 

80,181

 

 

 

238,056

 

 

 

 

 

 

 

 

Cash and cash equivalents, beginning of period

 

1,091,534

 

 

 

907,482

 

 

1,017,039

 

 

 

778,983

 

Cash and cash equivalents, end of period

$

1,097,220

 

 

$

1,017,039

 

$

1,097,220

 

 

$

1,017,039

 

DYNATRACE, INC.

GAAP to Non-GAAP Reconciliations

(Unaudited – In thousands, except percentages)

 

 

Three Months Ended March 31,

 

Twelve Months Ended March 31,

 

 

2026

 

 

 

2025

 

 

 

2026

 

 

 

2025

 

Non-GAAP cost of revenue:

 

 

 

 

 

 

 

Cost of revenue

$

101,395

 

 

$

85,094

 

 

$

372,204

 

 

$

320,192

 

Share-based compensation

 

(9,619

)

 

 

(9,659

)

 

 

(40,276

)

 

 

(36,924

)

Employer payroll taxes on employee stock transactions

 

(489

)

 

 

(661

)

 

 

(2,458

)

 

 

(2,447

)

Amortization of intangibles

 

(927

)

 

 

(734

)

 

 

(3,488

)

 

 

(13,262

)

Transaction, restructuring, and other

 

(1,475

)

 

 

 

 

 

(1,475

)

 

 

 

Non-GAAP cost of revenue

$

88,885

 

 

$

74,040

 

 

$

324,507

 

 

$

267,559

 

 

 

 

 

 

 

 

 

Non-GAAP gross profit:

 

 

 

 

 

 

 

Gross profit

$

430,321

 

 

$

360,071

 

 

$

1,646,183

 

 

$

1,378,491

 

Share-based compensation

 

9,619

 

 

 

9,659

 

 

 

40,276

 

 

 

36,924

 

Employer payroll taxes on employee stock transactions

 

489

 

 

 

661

 

 

 

2,458

 

 

 

2,447

 

Amortization of intangibles

 

927

 

 

 

734

 

 

 

3,488

 

 

 

13,262

 

Transaction, restructuring, and other

 

1,475

 

 

 

 

 

 

1,475

 

 

 

 

Non-GAAP gross profit

$

442,831

 

 

$

371,125

 

 

$

1,693,880

 

 

$

1,431,124

 

 

 

 

 

 

 

 

 

GAAP gross margin

 

81

%

 

 

81

%

 

 

82

%

 

 

81

%

Non-GAAP gross margin

 

83

%

 

 

83

%

 

 

84

%

 

 

84

%

 

 

 

 

 

 

 

 

Non-GAAP operating expenses:

 

 

 

 

 

 

 

Operating expenses

$

392,979

 

 

$

317,157

 

 

$

1,400,796

 

 

$

1,199,058

 

Share-based compensation

 

(63,380

)

 

 

(60,545

)

 

 

(259,350

)

 

 

(234,779

)

Employer payroll taxes on employee stock transactions

 

(2,719

)

 

 

(3,309

)

 

 

(12,834

)

 

 

(12,997

)

Amortization of intangibles

 

(20

)

 

 

(13

)

 

 

(56

)

 

 

(13,540

)

Transaction, restructuring, and other

 

(26,605

)

 

 

(52

)

 

 

(26,605

)

 

 

(158

)

Non-GAAP operating expenses

$

300,255

 

 

$

253,238

 

 

$

1,101,951

 

 

$

937,584

 

 

 

 

 

 

 

 

 

Non-GAAP income from operations:

 

 

 

 

 

 

 

Income from operations

$

37,342

 

 

$

42,914

 

 

$

245,387

 

 

$

179,433

 

Share-based compensation

 

72,999

 

 

 

70,204

 

 

 

299,626

 

 

 

271,703

 

Employer payroll taxes on employee stock transactions

 

3,208

 

 

 

3,970

 

 

 

15,292

 

 

 

15,444

 

Amortization of intangibles

 

947

 

 

 

747

 

 

 

3,544

 

 

 

26,802

 

Transaction, restructuring, and other

 

28,080

 

 

 

52

 

 

 

28,080

 

 

 

158

 

Non-GAAP income from operations

$

142,576

 

 

$

117,887

 

 

$

591,929

 

 

$

493,540

 

 

 

 

 

 

 

 

 

GAAP operating margin

 

7

%

 

 

10

%

 

 

12

%

 

 

11

%

Non-GAAP operating margin

 

27

%

 

 

26

%

 

 

29

%

 

 

29

%

DYNATRACE, INC.

GAAP to Non-GAAP Reconciliations

(Unaudited – In thousands, except per share data)

 

 

Three Months Ended March 31,

 

Twelve Months Ended March 31,

 

 

2026

 

 

 

2025

 

 

 

2026

 

 

 

2025

 

Non-GAAP net income:

 

 

 

 

 

 

 

Net income

$

17,416

 

 

$

39,304

 

 

 

162,669

 

 

 

483,684

 

Income tax expense (benefit)

 

29,399

 

 

 

16,400

 

 

 

137,092

 

 

 

(260,255

)

Non-GAAP effective cash tax

 

(28,223

)

 

 

(29,616

)

 

 

(117,584

)

 

 

(118,154

)

Interest income, net

 

(10,111

)

 

 

(10,930

)

 

 

(47,731

)

 

 

(48,281

)

Cash received from interest, net

 

9,614

 

 

 

10,776

 

 

 

43,296

 

 

 

46,927

 

Share-based compensation

 

72,999

 

 

 

70,204

 

 

 

299,626

 

 

 

271,703

 

Employer payroll taxes on employee stock transactions

 

3,208

 

 

 

3,970

 

 

 

15,292

 

 

 

15,444

 

Amortization of intangibles

 

947

 

 

 

747

 

 

 

3,544

 

 

 

26,802

 

Transaction, restructuring, and other

 

28,080

 

 

 

52

 

 

 

28,080

 

 

 

158

 

Loss (gain) on currency translation

 

638

 

 

 

(1,860

)

 

 

(6,643

)

 

 

4,285

 

Non-GAAP net income

$

123,967

 

 

$

99,047

 

 

$

517,641

 

 

$

422,313

 

 

 

 

 

 

 

 

 

Share count:

 

 

 

 

 

 

 

Weighted-average shares outstanding – basic

 

297,544

 

 

 

299,441

 

 

 

300,102

 

 

 

298,384

 

Weighted-average shares outstanding – diluted

 

298,925

 

 

 

304,354

 

 

 

303,727

 

 

 

303,602

 

 

 

 

 

 

 

 

 

Shares used in non-GAAP per share calculations:

 

 

 

 

 

 

 

Weighted-average shares outstanding – basic

 

297,544

 

 

 

299,441

 

 

 

300,102

 

 

 

298,384

 

Weighted-average shares outstanding – diluted

 

298,925

 

 

 

304,354

 

 

 

303,727

 

 

 

303,602

 

 

 

 

 

 

 

 

 

Non-GAAP net income per share:

 

 

 

 

 

 

 

Net income per share – basic

$

0.06

 

 

$

0.13

 

 

$

0.54

 

 

$

1.62

 

Net income per share – diluted

$

0.06

 

 

$

0.13

 

 

$

0.54

 

 

$

1.59

 

Non-GAAP net income per share – basic

$

0.42

 

 

$

0.33

 

 

$

1.72

 

 

$

1.42

 

Non-GAAP net income per share – diluted

$

0.41

 

 

$

0.33

 

 

$

1.70

 

 

$

1.39

 

 

Three Months Ended March 31,

Twelve Months Ended March 31,

 

 

2026

 

 

 

2025

 

 

2026

 

 

 

2025

 

Free cash flow:

 

 

 

 

 

 

Net cash provided by operating activities

$

226,361

 

 

$

162,790

 

$

561,850

 

 

$

459,419

 

Purchase of property and equipment

 

(13,958

)

 

 

(14,566

)

 

(32,173

)

 

 

(26,106

)

Capitalized software additions

 

 

 

 

(2,696

)

 

(194

)

 

 

(2,696

)

Free cash flow

$

212,403

 

 

$

145,528

 

$

529,483

 

 

$

430,617

 

 

Investor Contact:

Noelle Faris

VP, Investor Relations

[email protected]

Media Contact:

Stacy Gong

VP, Corporate Communications

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Data Management Security Apps/Applications Technology Software Networks Artificial Intelligence

MEDIA:

Logo
Logo

Westwater Resources Announces First Quarter 2026 Business Results

Westwater Resources Announces First Quarter 2026 Business Results

Company Continues Advancing Coosa Permitting Efforts, Customer Qualification Activities, and Kellyton Construction

CENTENNIAL, Colo.–(BUSINESS WIRE)–Westwater Resources, Inc. (NYSE American: WWR), an energy technology and battery-grade natural graphite company (“Westwater” or the “Company”), today announced business and financial results for the first quarter ended March 31, 2026.

“During the first quarter, we continued to advance our vertically integrated, mine-to-market graphite platform in Alabama,” said Frank Bakker, President and Chief Executive Officer of Westwater Resources. “Our focus remains on execution across Coosa permitting, qualification activities, and measured construction progress at Kellyton, while actively pursuing financing initiatives to support completion of Phase I. We are prioritizing non-dilutive and lower-cost capital where available, including potential government funding programs, as we work to build a domestic supply chain for battery-grade graphite.”

First Quarter 2026 Highlights

Coosa Graphite Deposit

  • Continued advancement of permitting activities for the Coosa Graphite Deposit (“Coosa”)

  • Received “covered project” designation under the FAST-41 Federal Permitting Program during the quarter

  • Filed application for a National Pollutant Discharge Elimination System (“NPDES”) permit with the Alabama Department of Environmental Management (“ADEM”), a key environmental permit associated with future mine development activities at Coosa

  • Continued geotechnical analyses, hydrologic monitoring, and permitting-related technical work

  • Continued preparation of the U.S. Army Corps of Engineers Individual Permit application and Alabama air permitting activities

  • Company believes the project is substantially past fieldwork risk related to cultural, wetland, and stream identification activities

Kellyton Graphite Plant

  • Continued construction and operational readiness activities at the Kellyton Graphite Plant (“Kellyton”)

  • Qualification line continued producing CSPG samples representative of future commercial production, positioning Westwater among the most advanced domestic graphite developers in the United States

  • Continued operation of the Company’s R&D Lab to support product optimization, customer qualification efforts, and in-house quality control testing

  • Approximately $130 million has been invested into Kellyton Phase I since inception of the project

  • Company continues to maintain its estimated Phase I capital cost of approximately $245 million, including approximately $19 million of untouched contingency and potential cost escalations

  • Initial production remains expected within approximately 12 months of securing the remaining project financing

Customer Engagement & Commercial Activities

  • Continued customer qualification and commercial engagement activities through the Company’s operational qualification line

  • Ongoing discussions with prospective customers, including global lithium-ion battery manufacturers and OEMs

  • Continued engagement with prospective customers evaluating U.S.-based sources of battery-grade graphite amid evolving industrial policy and critical mineral supply chain priorities

  • As previously announced, SK On Co., Ltd. elected to terminate the Products Procurement Agreement originally executed in February 2024

“Westwater’s integrated platform is aligned with both market demand and the federal government’s focus on domestic critical mineral supply chains,” added Mr. Bakker. “Our ability to produce CSPG samples today through the Kellyton qualification line, while advancing Coosa as a future domestic feedstock source, provides a clear point of differentiation as customers evaluate secure U.S.-based supply alternatives.”

Financing & Liquidity

  • Cash balance of approximately $41.5 million as of March 31, 2026

  • Raised approximately $1.2 million of net proceeds through the ATM Sales Agreement during the quarter

  • Approximately $70.6 million remained available under the ATM Sales Agreement as of March 31, 2026

  • Continued engagement on a variety of government funding opportunities, as well as on other capital markets opportunities with a preference for non-dilutive and lower-cost sources of capital

  • Company continues to maintain a measured approach to capital deployment while evaluating financing alternatives

First Quarter 2026 Financial Results

Net loss for the first quarter of 2026 was approximately $4.7 million, or $0.04 per share, compared to a net loss of approximately $2.7 million, or $0.04 per share, for the same period in 2025.

The increase in net loss was primarily related to increased permitting activities at Coosa, higher stock-based compensation expense, and increased product development and qualification activities.

Conference Call and Webcast

Westwater will host a conference call and webcast on May 13, 2026 at 11:00 AM Eastern Time to discuss its first quarter 2026 results and to provide a corporate update.

Webcast Link:

https://events.q4inc.com/attendee/265765325

Investors interested in submitting questions for management may do so in advance of the call by emailing [email protected]. A replay of the webcast will be available on the Company’s website following the event.

About Westwater Resources, Inc.

Westwater Resources, Inc. (NYSE American: WWR) is a critical minerals and energy technology company advancing a vertically integrated, mine-to-market platform for battery-grade natural graphite in the United States. The Company’s platform is anchored by the Coosa Graphite Deposit in Alabama, the largest natural flake graphite deposit in the contiguous United States, and the Kellyton Graphite Plant, a processing facility designed to produce coated spherical purified graphite (CSPG), a key material used in lithium-ion battery anodes. For more information, visit WestwaterResources.com.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words and phrases such as “continues advancing,” “results,” “execution,” “measured,” “actively pursuing,” “prioritizing,” “potential,” “future,” “believes,” “substantially,” “risk,” “most advanced,” “optimization,” “approximately,” “expected,” “prospective,” “evolving,” “priorities,” “aligned,” “clear point of differentiation,” “preference,” “measured,” “alternatives,” “increase,” “primarily,” and other similar words. Forward looking statements include, among other things, statements concerning: operational developments including the construction of the Kellyton Graphite Plant, the development of the Coosa Graphite Deposit, and the costs, schedules, production and economic projections associated with both of them, and strategic priorities including progress on financing for the Kellyton Graphite Plant. The Company cautions that there are factors that could cause actual results to differ materially from the forward-looking information that has been provided.

The reader is cautioned not to put undue reliance on this forward-looking information, which is not a guarantee of future performance and is subject to a number of uncertainties and other factors, many of which are outside the control of the Company; accordingly, there can be no assurance that such suggested results will be realized. Those uncertainties and other factors are discussed in Westwater’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent securities filings, and they could cause actual results to differ materially from management expectations.

Westwater Resources, Inc.

Email: [email protected]

Investor Relations

Email: [email protected]

KEYWORDS: Colorado Africa Australia/Oceania United States Canada North America Australia

INDUSTRY KEYWORDS: Other Energy Mining/Minerals Technology Batteries Energy Natural Resources

MEDIA:

Logo
Logo